Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Otorhinolaryngology

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 654 articles:
HTML format



Single Articles


    July 2021
  1. XU Y, Chen M, Guo Q, Peng H, et al
    Percutaneous endoscopic gastrostomy can improve survival outcomes in patients with N3 nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy.
    Oral Oncol. 2021;121:105435.
    PubMed     Abstract available


  2. ALMANGUSH A, Alabi RO, Makitie AA, Leivo I, et al
    Machine learning in head and neck cancer: Importance of a web-based prognostic tool for improved decision making.
    Oral Oncol. 2021 Jul 12:105452. doi: 10.1016/j.oraloncology.2021.105452.
    PubMed    


  3. KOUKETSU A, Miyashita H, Kojima I, Sakamoto M, et al
    Comparison of different diagnostic imaging techniques for the detection of bone invasion in oral cancers.
    Oral Oncol. 2021;120:105453.
    PubMed     Abstract available


  4. MERCHANT YP, Kudpaje A, Rao VUS
    Extent of neck dissection in the N+ neck: Adjudicating a Conundrum!
    Oral Oncol. 2021 Jul 11:105441. doi: 10.1016/j.oraloncology.2021.105441.
    PubMed    


  5. IQBAL MS, Kovarik J, Patil R, Kelly CG, et al
    Are taxanes more effective than 5FU in combination chemotherapy for recurrent and metastatic head and neck cancer?
    Oral Oncol. 2021 Jul 9:105455. doi: 10.1016/j.oraloncology.2021.105455.
    PubMed    


  6. IMADUDDIN M, Sultania M, Vigneshwaran B, Muduly DK, et al
    Psychosocial Factors in an Oral Cancer Survivor Leading to Delay in Seeking Help.
    Oral Oncol. 2021 Jul 5:105438. doi: 10.1016/j.oraloncology.2021.105438.
    PubMed    


  7. WILKIE MD, Lancaster J, Roland NJ, Jones TM, et al
    Elective management of regional nodal basins in cutaneous squamous cell carcinoma of the head and neck: Controversies and contemporary perspectives.
    Oral Oncol. 2021;120:105432.
    PubMed     Abstract available


  8. KIM SY, Beer M, Tshering Vogel DW
    Imaging in head and neck cancers: Update for non-radiologist.
    Oral Oncol. 2021;120:105434.
    PubMed     Abstract available


  9. FARLOW JL, Brenner JC, Lei YL, Chinn SB, et al
    Immune deserts in head and neck squamous cell carcinoma: A review of challenges and opportunities for modulating the tumor immune microenvironment.
    Oral Oncol. 2021;120:105420.
    PubMed     Abstract available


    June 2021
  10. PATEL KB, Mroz EA, Faquin WC, Rocco JW, et al
    A combination of intra-tumor genetic heterogeneity, estrogen receptor alpha and human papillomavirus status predicts outcomes in head and neck squamous cell carcinoma following chemoradiotherapy.
    Oral Oncol. 2021;120:105421.
    PubMed     Abstract available


  11. RIBEIRO IP, Lopes T, Pedro N, Barroso L, et al
    Should sitting time be a treatment target in head and neck cancer patients receiving curative treatment?
    Oral Oncol. 2021 Jun 26:105418. doi: 10.1016/j.oraloncology.2021.105418.
    PubMed    


  12. YANG J, Wan SQ, Huang L, Zhong WJ, et al
    Analysis of hospitalization costs and length of stay for oral cancer patients undergoing surgery: Evidence from Hunan, China.
    Oral Oncol. 2021;119:105363.
    PubMed     Abstract available


  13. AMBRE S, Sultania M, Biswal S, Mitra S, et al
    Poorly differentiated "insular" thyroid carcinoma with solitary vascular mandibular metastasis - A rare histology and management.
    Oral Oncol. 2021 Jun 24:105416. doi: 10.1016/j.oraloncology.2021.105416.
    PubMed    


  14. ZHU MY, Wu HJ, Miao JJ, Di MP, et al
    Radiation-induced hypothyroidism in patients with nasopharyngeal carcinoma treated with intensity-modulated radiation therapy with or without chemotherapy: Development of a nomogram based on the equivalent dose.
    Oral Oncol. 2021;120:105378.
    PubMed     Abstract available


  15. LENZE NR, Farquhar DR, Sheth S, Zevallos JP, et al
    Prognostic impact of socioeconomic status compared to overall stage for HPV-negative head and neck squamous cell carcinoma.
    Oral Oncol. 2021;119:105377.
    PubMed     Abstract available


  16. LIEN MY, Wang TH, Hsieh CY, Tsai MH, et al
    Both combined or sequential use with immune checkpoint inhibitors on cetuximab-treated patients with recurrent or metastatic head and neck squamous cell carcinoma improve the overall survival.
    Oral Oncol. 2021;119:105380.
    PubMed     Abstract available


  17. KAVARTHAPU A, Gurumoorthy K
    Linking chronic periodontitis and oral cancer: A review.
    Oral Oncol. 2021 Jun 14:105375. doi: 10.1016/j.oraloncology.2021.105375.
    PubMed     Abstract available


  18. MA C, Sheng S, Shen Y, Gao W, et al
    A comparative study on using superior thyroid artery perforator flaps versus traditional sternocleidomastoid myocutaneous flaps for reconstructions after oral cancer ablation: "New tricks for old dogs"?
    Oral Oncol. 2021 Jun 11:105374. doi: 10.1016/j.oraloncology.2021.105374.
    PubMed     Abstract available


  19. BRAS L, de Vries J, Festen S, Steenbakkers RJHM, et al
    Frailty and restrictions in geriatric domains are associated with surgical complications but not with radiation-induced acute toxicity in head and neck cancer patients: A prospective study.
    Oral Oncol. 2021;118:105329.
    PubMed     Abstract available


  20. KARABAJAKIAN A, Bouaoud J, Michon L, Kamal M, et al
    Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity.
    Oral Oncol. 2021;119:105368.
    PubMed     Abstract available


  21. XU J, Wang R, Wang T, Wang T, et al
    Targeted DNA profiling and the prevalence of NTRK aberrations in Chinese patients with head and neck cancer.
    Oral Oncol. 2021;119:105369.
    PubMed     Abstract available


    May 2021
  22. TECKIE S, Wotman M, Marziliano A, Orner D, et al
    Patterns of alcohol use among early head and neck cancer survivors: A cross-sectional survey study using the alcohol use disorders identification test (AUDIT).
    Oral Oncol. 2021;119:105328.
    PubMed     Abstract available


  23. DE FELICE F, Lei M, Oakley R, Lyons A, et al
    Risk stratified follow up for head and neck cancer patients - An evidence based proposal.
    Oral Oncol. 2021;119:105365.
    PubMed     Abstract available


  24. LIN MC, Leu YS, Chiang CJ, Ko JY, et al
    Adequate surgical margins for oral cancer: A Taiwan cancer registry national database analysis.
    Oral Oncol. 2021;119:105358.
    PubMed     Abstract available


  25. PENG Y, Xiao L, Rong H, Ou Z, et al
    Single-cell profiling of tumor-infiltrating TCF1/TCF7(+) T cells reveals a T lymphocyte subset associated with tertiary lymphoid structures/organs and a superior prognosis in oral cancer.
    Oral Oncol. 2021;119:105348.
    PubMed     Abstract available


  26. DESIDERI I, Becherini C, Belgioia L, Merlotti A, et al
    Palliative radiotherapy in older adults with head and neck squamous cell carcinoma: A systematic review.
    Oral Oncol. 2021;119:105355.
    PubMed     Abstract available


  27. BERZENJI D, Sewnaik A, Keereweer S, Monserez DA, et al
    Dissemination patterns and chronology of distant metastasis affect survival of patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2021;119:105356.
    PubMed     Abstract available


  28. SCHOONBEEK RC, Bult FFS, Plaat BEC, Witjes MJH, et al
    Incidental findings during the diagnostic work-up in the head and neck cancer pathway: Effects on treatment delay and survival.
    Oral Oncol. 2021;118:105350.
    PubMed     Abstract available


  29. CHEN X, Li Y, Li X, Cao X, et al
    An interpretable machine learning prognostic system for locoregionally advanced nasopharyngeal carcinoma based on tumor burden features.
    Oral Oncol. 2021;118:105335.
    PubMed     Abstract available


  30. PATTERSON JM, Lu L, Watson LJ, Harding S, et al
    Trends in, and predictors of, swallowing and social eating outcomes in head and neck cancer survivors: A longitudinal analysis of head and neck 5000.
    Oral Oncol. 2021;118:105344.
    PubMed     Abstract available


  31. AL-QURAYSHI Z, Randolph GW, Kandil E
    Cost-effectiveness of computed tomography nodal scan in patients with papillary thyroid carcinoma.
    Oral Oncol. 2021;118:105326.
    PubMed     Abstract available


  32. VENTURA TMO, Santos PSS, Ribeiro NR, de Lima Leite A, et al
    Is there difference in the comparative and quantitative salivary proteome between stimulated and unstimulated saliva in head and neck cancer patients treated by radiotherapy?
    Oral Oncol. 2021 May 10:105315. doi: 10.1016/j.oraloncology.2021.105315.
    PubMed     Abstract available


    April 2021
  33. DA SILVA LEONEL ACL, Ribeiro ILA, de Souza MLM, Kaminagakura E, et al
    COVID-19, changes in smoking behaviour, and head and neck cancer: Current data and future perspectives.
    Oral Oncol. 2021 Apr 30:105327. doi: 10.1016/j.oraloncology.2021.105327.
    PubMed    


  34. ZONG J, Liu Y, Liang Q, Xu H, et al
    Administration of oral maintenance chemotherapy for 1 year following definitive chemoradiotherapy may improve the survival of patients with stage N3 nasopharyngeal carcinoma.
    Oral Oncol. 2021;118:105313.
    PubMed     Abstract available


  35. SINHA NK, Kohli PS, Nagarajan K, Gochhait D, et al
    A nomogram for predicting the risk of neck node metastasis in oral cavity carcinoma using acoustic radiation force impulse imaging (ARFI).
    Oral Oncol. 2021;118:105311.
    PubMed     Abstract available


  36. CHEN JL, Wang Q, Huang LM, Xu YH, et al
    A rare case of Kimura disease with lumps on the cheek and behind the ear.
    Oral Oncol. 2021 Apr 28:105303. doi: 10.1016/j.oraloncology.2021.105303.
    PubMed    


  37. LYNCH PT, Horani S, Lee R, Sumer BD, et al
    Effectiveness of physical activity interventions in improving objective and patient-reported outcomes in head and neck cancer survivors: A systematic review.
    Oral Oncol. 2021;117:105253.
    PubMed     Abstract available


  38. VALLINA C, Lopez-Pintor RM, Gonzalez-Serrano J, de Vicente JC, et al
    Genes involved in the epithelial-mesenchymal transition in oral cancer: A systematic review.
    Oral Oncol. 2021;117:105310.
    PubMed     Abstract available


  39. FANNY C, Sebastien L, Pascale G, Antoine N, et al
    Physician practice variation in head and neck cancer therapy: Results of a national survey.
    Oral Oncol. 2021;117:105293.
    PubMed     Abstract available


  40. MOUTAFI M, Economopoulou P, Rimm D, Psyrri A, et al
    PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data.
    Oral Oncol. 2021;117:105292.
    PubMed     Abstract available


  41. XIANG ZF, Hu DF, Xiong HC, Li MY, et al
    Benefit of chemotherapy in stage III nasopharyngeal carcinoma: Analysis of the surveillance, epidemiology, and end results database.
    Oral Oncol. 2021;117:105284.
    PubMed     Abstract available


  42. KUMAR R, Dheeraj K
    Do ipsilateral lateralized squamous cell carcinomas of oral tongue with a depth of invasion (DOI) greater than 10 mm warrant a bilateral neck dissection to prevent future regional recurrences on contralateral side? A continuing conundrum.
    Oral Oncol. 2021 Apr 7:105285. doi: 10.1016/j.oraloncology.2021.105285.
    PubMed    


  43. SCHREIBER A, Mattavelli D, Accorona R, Rampinelli V, et al
    Endoscopic-assisted multi-portal compartmental resection of the masticatory space in oral cancer: Anatomical study and preliminary clinical experience.
    Oral Oncol. 2021;117:105269.
    PubMed     Abstract available


  44. SAKTHIVEL P, Raveendran S, Panda S, Singh CA, et al
    Synchronous primary neoplasia in patients with p16 positive oropharyngeal carcinoma: Does the 2nd cancer really matters?
    Oral Oncol. 2021;115:105113.
    PubMed    


    March 2021
  45. SWAIN M, Ghosh-Laskar S
    Stereotactic body radiotherapy (SBRT) for primary non-metastatic head and neck cancer: When less is enough.
    Oral Oncol. 2021;116:105265.
    PubMed     Abstract available


  46. IQBAL MS, Morgan D, West N, Paterson C, et al
    Hypofractionated chemoradiation (2.75 Gy per fraction) in Head and Neck Cancer: Extreme caution required.
    Oral Oncol. 2021 Mar 21:105261. doi: 10.1016/j.oraloncology.2021.105261.
    PubMed    


  47. CAO C, Gan X, He Y, Su Y, et al
    Diagnostic efficacy of PET-CT, CT, and MRI in preoperative assessment of mandibular invasion caused by head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2021;116:105264.
    PubMed     Abstract available


  48. PUCCI R, Cassoni A, Battisti A, Valentini V, et al
    Covid-19 pandemic and head and neck cancers, what should we expect?
    Oral Oncol. 2021 Mar 15:105263. doi: 10.1016/j.oraloncology.2021.105263.
    PubMed    


  49. TANI R, Ito N, Matsui K, Yamasaki S, et al
    MICA A5.1 homozygous genotype is associated with a risk for early-onset oral cancer.
    Oral Oncol. 2021;116:105256.
    PubMed     Abstract available


  50. DIANA G, Corica C
    Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence?
    Oral Oncol. 2021;115:105168.
    PubMed     Abstract available


  51. KIM HAJ, Zeng PYF, Shaikh MH, Mundi N, et al
    All HPV-negative head and neck cancers are not the same: Analysis of the TCGA dataset reveals that anatomical sites have distinct mutation, transcriptome, hypoxia, and tumor microenvironment profiles.
    Oral Oncol. 2021;116:105260.
    PubMed     Abstract available


  52. ILHAN B, Guneri P, Wilder-Smith P
    The contribution of artificial intelligence to reducing the diagnostic delay in oral cancer.
    Oral Oncol. 2021;116:105254.
    PubMed     Abstract available


  53. MO Y, Zhang B, Pan Y, Qin Q, et al
    Impact of the weekday of the first intensity-modulated radiotherapy treatment on the survival outcomes of patients with nasopharyngeal carcinoma: A multicenter cohort study.
    Oral Oncol. 2021;116:105258.
    PubMed     Abstract available


  54. LAN R, Catherine JH, Chossegros C, Campana F, et al
    Temporal association between the introduction of public health programs and interest in oral cancers on the internet in the European Union.
    Oral Oncol. 2021 Mar 5:105250. doi: 10.1016/j.oraloncology.2021.105250.
    PubMed    


  55. CHUMPITAZ-CERRATE V, Chavez-Rimache L, Rodriguez-Flores A
    Challenges in the early diagnosis of oral cancer in rural populations in Peru during the COVID-19 pandemic.
    Oral Oncol. 2021 Mar 1:105251. doi: 10.1016/j.oraloncology.2021.105251.
    PubMed    


    February 2021
  56. AWAN MJ, Gittleman H, Barnholtz-Sloan J, Machtay M, et al
    Risk groups of laryngeal cancer treated with chemoradiation according to nomogram scores - A pooled analysis of RTOG 0129 and 0522.
    Oral Oncol. 2021;116:105241.
    PubMed     Abstract available


  57. DEVARAJA K
    Erratum to "The surgical sequence of neck dissection and primary tumor excision could impact the locoregional recurrence rates in oral squamous cell carcinoma" [Oral Oncol. 110 (2020) 104809].
    Oral Oncol. 2021 Feb 24:105229. doi: 10.1016/j.oraloncology.2021.105229.
    PubMed    


  58. ZSCHAECK S, Weingartner J, Ghadjar P, Wust P, et al
    Fever range whole body hyperthermia for re-irradiation of head and neck squamous cell carcinomas: Final results of a prospective study.
    Oral Oncol. 2021;116:105240.
    PubMed     Abstract available


  59. LIN M, Yang Q, You R, Zou X, et al
    Metastatic characteristics associated with survival of synchronous metastatic nasopharyngeal carcinoma in non-epidemic areas.
    Oral Oncol. 2021;115:105200.
    PubMed     Abstract available


  60. NORTH LM, Harvey E, Vanle B, Shreenivas A, et al
    Frequent omission of radiation after flap reconstruction of head and neck cancer: Are we dooming patients to failure?
    Oral Oncol. 2021 Feb 18:105225. doi: 10.1016/j.oraloncology.2021.105225.
    PubMed    


  61. HUANG L, Zhang X, Bai Y, Chua KLM, et al
    Efficacy and safety of apatinib in recurrent/metastatic nasopharyngeal carcinoma: A pilot study.
    Oral Oncol. 2021;115:105222.
    PubMed     Abstract available


  62. SANTOSO AMM, Jansen F, Lissenberg-Witte BI, Baatenburg de Jong RJ, et al
    Sleep quality trajectories from head and neck cancer diagnosis to six months after treatment.
    Oral Oncol. 2021;115:105211.
    PubMed     Abstract available


  63. LEON X, Orus C, Casasayas M, Neumann E, et al
    Trends in disease-specific survival of head and neck squamous cell carcinoma patients treated in a single institution over a 30-year period.
    Oral Oncol. 2021;115:105184.
    PubMed     Abstract available


  64. GALLO O, Locatello LG
    All that glitters is not gold: Clinical implications from the genetic analysis of head and neck cancer recurrences.
    Oral Oncol. 2021 Feb 10:105187. doi: 10.1016/j.oraloncology.2021.105187.
    PubMed    


  65. MA SJ, Iovoli AJ, Attwood K, Wooten KE, et al
    Association of significant financial burden with survival for head and neck cancer patients treated with radiation therapy.
    Oral Oncol. 2021;115:105196.
    PubMed     Abstract available


  66. ADKINS DR, Lin JC, Sacco A, Ley J, et al
    Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naive, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial.
    Oral Oncol. 2021;115:105192.
    PubMed     Abstract available


  67. MENEZES FDS, Fernandes GA, Antunes JLF, Villa LL, et al
    Global incidence trends in head and neck cancer for HPV-related and -unrelated subsites: A systematic review of population-based studies.
    Oral Oncol. 2021;115:105177.
    PubMed     Abstract available


  68. VIGANO A, De Felice F, Iacovelli NA, Alterio D, et al
    M. D. Anderson symptom inventory head neck (MDASI-HN) questionnaire: Italian language psychometric validation in head and neck cancer patients treated with radiotherapy +/- systemic therapy - A study of the Italian Association of Radiotherapy and Clin
    Oral Oncol. 2021;115:105189.
    PubMed     Abstract available


  69. OH LJ, Satgunaseelan L, Asher R, Veness M, et al
    Young age is not a predictor of disease specific survival in oral cancer: A multi-institutional study.
    Oral Oncol. 2021;115:105162.
    PubMed     Abstract available


  70. ADKINS D, Ley J, Atiq O, Powell S, et al
    Nanoparticle albumin-bound paclitaxel with cetuximab and carboplatin as first-line therapy for recurrent or metastatic head and neck cancer: A single-arm, multicenter, phase 2 trial.
    Oral Oncol. 2021;115:105173.
    PubMed     Abstract available


    January 2021
  71. THADURI A, Chadha L, Poonia DR, Rajkumar KS, et al
    Oral cancer screening - A delphic horizon in India.
    Oral Oncol. 2021 Jan 26:105174. doi: 10.1016/j.oraloncology.2020.105174.
    PubMed    


  72. MA HH, Chen DS, Li S, Xiao MZ, et al
    The value and inadequacy of tumor mutation burden on efficacy of immune checkpoint inhibitors in head and neck cancers.
    Oral Oncol. 2021 Jan 26:105179. doi: 10.1016/j.oraloncology.2021.105179.
    PubMed    


  73. JELINEK MJ, Foster NR, Zoroufy AJ, Schwartz GK, et al
    A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.
    Oral Oncol. 2021;114:105171.
    PubMed     Abstract available


  74. CHAN SK, Chan SY, Tong CC, Lam KO, et al
    Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carc
    Oral Oncol. 2021;114:105158.
    PubMed     Abstract available


  75. HOWLETT J, Hamilton S, Ye A, Jewett D, et al
    Treatment and outcomes of nasopharyngeal carcinoma in a unique non-endemic population.
    Oral Oncol. 2021;114:105182.
    PubMed     Abstract available


  76. MARTELLI AJ, Machado RA, Pereira WM, Silveira DMM, et al
    Impact of the COVID-19 pandemic in the head and neck cancer treatment in the Brazil.
    Oral Oncol. 2021 Jan 18:105148. doi: 10.1016/j.oraloncology.2020.105148.
    PubMed    


  77. DEVARAJA K
    De-escalation of aggressive adjuvant therapy for limited extranodal extension in head and neck cancer.
    Oral Oncol. 2021 Jan 18:105161. doi: 10.1016/j.oraloncology.2020.105161.
    PubMed    


  78. VARELA-CENTELLES P, Seoane J, Bilbao A, Seoane-Romero J, et al
    Covid-19 pandemic: A new contributing factor to diagnostic and treatment delay in oral cancer patients.
    Oral Oncol. 2021 Jan 15:105176. doi: 10.1016/j.oraloncology.2020.105176.
    PubMed    


  79. JOHNSON D, Ma BBY
    Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma.
    Oral Oncol. 2021;113:105127.
    PubMed     Abstract available


  80. TREVISIOL C, Gion M, Vaona A, Fabricio ASC, et al
    The appropriate use of circulating EBV-DNA in nasopharyngeal carcinoma: Comprehensive clinical practice guidelines evaluation.
    Oral Oncol. 2021;114:105128.
    PubMed     Abstract available


  81. EMMETT SE, Stark MS, Pandeya N, Panizza B, et al
    MicroRNA expression is associated with human papillomavirus status and prognosis in mucosal head and neck squamous cell carcinomas.
    Oral Oncol. 2021;113:105136.
    PubMed     Abstract available


    December 2020
  82. LORINI L, Merlano M, Licitra L, Ravanelli M, et al
    Brain metastasis in head and neck squamous cell carcinoma after immune check point inhibitors treatment.
    Oral Oncol. 2020 Dec 31:105138. doi: 10.1016/j.oraloncology.2020.105138.
    PubMed    


  83. VIPPARTHI K, Patel AK, Ghosh S, Das S, et al
    Two novel cell culture models of buccal mucosal oral cancer from patients with no risk-habits of tobacco smoking or chewing.
    Oral Oncol. 2020;113:105131.
    PubMed     Abstract available


  84. PELLINI R, Campo F, Sergi D, Cappuzzo F, et al
    Role of Pembrolizumab in recurrent or metastatic head and neck carcinoma.
    Oral Oncol. 2020 Dec 29:105133. doi: 10.1016/j.oraloncology.2020.105133.
    PubMed    


  85. ALMANGUSH A, Makitie AA, Leivo I
    Back to basics: Hematoxylin and eosin staining is the principal tool for histopathological risk assessment of oral cancer.
    Oral Oncol. 2020 Dec 29:105134. doi: 10.1016/j.oraloncology.2020.105134.
    PubMed    


  86. MATSUO M, Yasumatsu R, Masuda M, Toh S, et al
    Drug-induced interstitial lung disease in recurrent and/or metastatic head and neck cancer patients treated with cetuximab and/or nivolumab.
    Oral Oncol. 2020;113:105129.
    PubMed     Abstract available


  87. SUBRAMANIAM N, Clark JR, Goldstein D, de Almeida J, et al
    Geographical heterogeneity in the American Joint committee on Cancer oral cancer staging and prognostic implications.
    Oral Oncol. 2020;113:105122.
    PubMed     Abstract available


  88. NOEL CW, Sutradhar R, Li Q, Forner D, et al
    Chinese and South Asian ethnicity, immigration status and head and neck cancer outcomes: A population based study.
    Oral Oncol. 2020;113:105118.
    PubMed     Abstract available


    November 2020
  89. KOBAYASHI K, Yoshimoto S, Ando M, Matsumoto F, et al
    Full-coverage TP53 deep sequencing of recurrent head and neck squamous cell carcinoma facilitates prognostic assessment after recurrence.
    Oral Oncol. 2020;113:105091.
    PubMed     Abstract available


  90. MAZUL AL, Naik AN, Zhan KY, Stepan KO, et al
    Gender and race interact to influence survival disparities in head and neck cancer.
    Oral Oncol. 2020;112:105093.
    PubMed     Abstract available


  91. MASHIANA SS, Navale P, Khandakar B, Sobotka S, et al
    Human papillomavirus genotype distribution in head and neck cancer: Informing developing strategies for cancer prevention, diagnosis, treatment and surveillance.
    Oral Oncol. 2020;113:105109.
    PubMed     Abstract available


  92. ROY D, Patel A, Goswami G, Samantaray S, et al
    Role of Onco rehabilitation in head and neck cancer.
    Oral Oncol. 2020 Nov 19:105015. doi: 10.1016/j.oraloncology.2020.105015.
    PubMed    


  93. KHAN SA, Burke M, Zhu F, Yang DH, et al
    Survivin expression and impact on head and neck cancer outcomes.
    Oral Oncol. 2020;112:105049.
    PubMed     Abstract available


  94. ZHAO XT, Zhu Y, Zhou JF, Gao YJ, et al
    Development of a novel 7 immune-related genes prognostic model for oral cancer: A study based on TCGA database.
    Oral Oncol. 2020;112:105088.
    PubMed     Abstract available


  95. CHAKRABARTI D, Akhtar N, Qayoom S, Rajan S, et al
    Optimising elective neck dissection for early oral cancers.
    Oral Oncol. 2020 Nov 13:105090. doi: 10.1016/j.oraloncology.2020.105090.
    PubMed    


  96. WIJETUNGA NA, Yu Y, Morris LG, Lee N, et al
    The head and neck cancer genome in the era of immunotherapy.
    Oral Oncol. 2020;112:105040.
    PubMed     Abstract available


  97. ZHAI TT, Wesseling F, Langendijk JA, Shi Z, et al
    External validation of nodal failure prediction models including radiomics in head and neck cancer.
    Oral Oncol. 2020;112:105083.
    PubMed     Abstract available


  98. REGO-LORCA D, Burgos-Blasco B, Hernandez-Garcia E, Domingo-Gordo B, et al
    Abducens palsy as first manifestation of a nasopharyngeal carcinoma.
    Oral Oncol. 2020 Nov 10:105079. doi: 10.1016/j.oraloncology.2020.105079.
    PubMed    


  99. LIU AK, Wu J, Berthelet E, Lalani N, et al
    Clinical features of head and neck cancer patients with brain metastases: A retrospective study of 88 cases.
    Oral Oncol. 2020;112:105086.
    PubMed     Abstract available


  100. CHO JH, Lim YC
    Prognostic impact of regulatory T cell in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2020;112:105084.
    PubMed     Abstract available


  101. HANNA GJ, Rettig EM, Park JC, Varvares MA, et al
    Hospitalization rates and 30-day all-cause mortality among head and neck cancer patients and survivors with COVID-19.
    Oral Oncol. 2020;112:105087.
    PubMed     Abstract available


  102. AMPIL F, Cuellar H, Nathan CA, Smith D, et al
    Recurrent head and neck cancers in the skull base, stereotactic radiosurgery palliation, and risk prognosticators.
    Oral Oncol. 2020 Nov 3:105005. doi: 10.1016/j.oraloncology.2020.105005.
    PubMed    


  103. SAKTHIVEL P, Samy K, Panda S, Amit Singh C, et al
    14 "S" in head and neck cancers.
    Oral Oncol. 2020;112:105070.
    PubMed    


    October 2020
  104. AMPIL FL, Nathan CA, Asarkar A
    Long-term survival in patients with intermediate-risk head and neck cancer treated with adjuvant radiotherapy.
    Oral Oncol. 2020 Oct 30:105071. doi: 10.1016/j.oraloncology.2020.105071.
    PubMed    


  105. PANDOLFINI M, Di Stadio A, Brenner MJ, Pichi B, et al
    Airway obstruction from tracheostomy balloon cuff herniation during oral cancer asportation. Emergency successfully managed and lessons learnt from device malfunction.
    Oral Oncol. 2020 Oct 29:105048. doi: 10.1016/j.oraloncology.2020.105048.
    PubMed     Abstract available


  106. SAIDAK Z, Galmiche A, Lottin M, Montes L, et al
    The coagulome of Head and Neck Squamous Cell Carcinoma.
    Oral Oncol. 2020 Oct 28:105068. doi: 10.1016/j.oraloncology.2020.105068.
    PubMed    


  107. IMADUDDIN M, Sultania M, Vigneshwaran B, Muduly DK, et al
    Metronomic therapy using Methotrexate and Celecoxib: A Boon for Oral Cancer patients during COVID-19 Pandemic.
    Oral Oncol. 2020 Oct 24:105069. doi: 10.1016/j.oraloncology.2020.105069.
    PubMed    


  108. MORIKAWA T, Shibahara T, Takano M, Iwamoto M, et al
    Countermeasure and opportunistic screening systems for oral cancer.
    Oral Oncol. 2020;112:105047.
    PubMed     Abstract available


  109. GUPTA T, Ghosh-Laskar S, Agarwal JP
    Resource-sparing curative-intent hypofractionated-accelerated radiotherapy in head and neck cancer: More relevant than ever before in the COVID era.
    Oral Oncol. 2020;111:105045.
    PubMed     Abstract available


  110. LEK SM, Li K, Tan QX, Shannon NB, et al
    Pairing a prognostic target with potential therapeutic strategy for head and neck cancer.
    Oral Oncol. 2020;111:105035.
    PubMed     Abstract available


  111. FERRARI M, Paderno A, Giannini L, Cazzador D, et al
    COVID-19 screening protocols for preoperative assessment of head and neck cancer patients candidate for elective surgery in the midst of the pandemic: A narrative review with comparison between two Italian institutions.
    Oral Oncol. 2020;112:105043.
    PubMed     Abstract available


  112. PARK JC, Durbeck J, Clark JR, Faden DL, et al
    Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes.
    Oral Oncol. 2020;111:105024.
    PubMed     Abstract available


  113. DE VRIES J, Bras L, Sidorenkov G, Festen S, et al
    Frailty is associated with decline in health-related quality of life of patients treated for head and neck cancer.
    Oral Oncol. 2020;111:105020.
    PubMed     Abstract available


  114. HUANG S, Piao Y, Cao C, Chen J, et al
    A prospective randomized controlled trial on the value of prophylactic oral nutritional supplementation in locally advanced nasopharyngeal carcinoma patients receiving chemo-radiotherapy.
    Oral Oncol. 2020;111:105025.
    PubMed     Abstract available


  115. SUBRAMANIAM N, Dhar SK, Rao R, Prasad K, et al
    Novel tyrosine metabolites in the transcriptomic profiling of smokeless tobacco related oral cancer and their potential implications.
    Oral Oncol. 2020 Oct 1:105027. doi: 10.1016/j.oraloncology.2020.105027.
    PubMed    


  116. CUSTODIO M, Biddle A, Tavassoli M
    Portrait of a CAF: The story of cancer-associated fibroblasts in head and neck cancer.
    Oral Oncol. 2020;110:104972.
    PubMed     Abstract available


    September 2020
  117. CHOW JCH, Tam AHP, Cheung KM, Lee VHF, et al
    Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG.
    Oral Oncol. 2020;111:105012.
    PubMed     Abstract available


  118. ECONOMOPOULOU P, Kotsantis I, Papaxoinis G, Gavrielatou N, et al
    Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Oral Oncol. 2020;111:105013.
    PubMed     Abstract available


  119. RAPADO-GONZALEZ O, Muinelo-Romay L, Suarez-Cunqueiro MM
    Letter to the editor: "Liquid biopsy based on saliva cell-free DNA as a potential biomarker for head and neck cancer".
    Oral Oncol. 2020 Sep 21:105016. doi: 10.1016/j.oraloncology.2020.105016.
    PubMed    


  120. YETE S, Saranath D
    MicroRNAs in oral cancer: Biomarkers with clinical potential.
    Oral Oncol. 2020;110:105002.
    PubMed     Abstract available


  121. YEH CF, Ho CY, Chin YC, Shu CH, et al
    Pretreatment age and serum lactate dehydrogenase as predictors of synchronous second primary cancer in patients with nasopharyngeal carcinoma.
    Oral Oncol. 2020;110:104990.
    PubMed     Abstract available


  122. GRILLI G, Hermida-Prado F, Alvarez-Fernandez M, Allonca E, et al
    Impact of notch signaling on the prognosis of patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2020;110:105003.
    PubMed     Abstract available


  123. ZHANG L, Li B, Peng Y, Wu F, et al
    The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study.
    Oral Oncol. 2020;110:104943.
    PubMed     Abstract available


  124. TU X, Ren J, Zhao Y
    Prognostic value of prognostic nutritional index in nasopharyngeal carcinoma: A meta-analysis containing 4511 patients.
    Oral Oncol. 2020;110:104991.
    PubMed     Abstract available


  125. MARTIN M, Sautois B
    Early onset of head and neck squamous-cell carcinoma and fatal toxicity with concurrent chemoradiotherapy in a patient compound heterozygote for FANCA gene.
    Oral Oncol. 2020 Sep 1:104989. doi: 10.1016/j.oraloncology.2020.104989.
    PubMed    


  126. HERRERA GOMEZ RG, Saleh K, Mayache L, Iacob M, et al
    Panitumumab as an effective maintenance treatment in metastatic squamous cell carcinoma of the head and neck.
    Oral Oncol. 2020 Sep 1:104984. doi: 10.1016/j.oraloncology.2020.104984.
    PubMed    


  127. WANG M, Zhu F, Luo N, Han T, et al
    A case report of a patient with first phenotype of papillary thyroid carcinoma and heterochronous multiprimary tumor harboring germline MUTYH Arg19*/Gly286Glu mutations.
    Oral Oncol. 2020 Sep 1:104987. doi: 10.1016/j.oraloncology.2020.104987.
    PubMed     Abstract available


    August 2020
  128. HE L, Xiao J, Wei Z, He Y, et al
    Toxicity and dosimetric analysis of nasopharyngeal carcinoma patients undergoing radiotherapy with IMRT or VMAT: A regional center's experience.
    Oral Oncol. 2020;109:104978.
    PubMed     Abstract available


  129. SCOTT SE, Oakley R, Moller H, Warburton F, et al
    Tracking cancer occurrence in the 5 years after referral for suspected head and neck cancer.
    Oral Oncol. 2020;109:104955.
    PubMed     Abstract available


  130. ELBEHI AM, Anu RI, Ekine-Afolabi B, Cash E, et al
    Emerging role of immune checkpoint inhibitors and predictive biomarkers in head and neck cancers.
    Oral Oncol. 2020;109:104977.
    PubMed     Abstract available


  131. SINGH A, Singh CA, Sikka K
    Classification of three prognostically different groups of Head and Neck Cancer patients based on their metabolic response to induction chemotherapy (IC-1).
    Oral Oncol. 2020 Aug 21:104936. doi: 10.1016/j.oraloncology.2020.104936.
    PubMed    


  132. SHAIKH MH, Barrett JW, Khan MI, Kim HAJ, et al
    Chromosome 3p loss in the progression and prognosis of head and neck cancer.
    Oral Oncol. 2020;109:104944.
    PubMed     Abstract available


  133. BARLAK N, Capik O, Sanli F, Karatas OF, et al
    The roles of microRNAs in the stemness of oral cancer cells.
    Oral Oncol. 2020;109:104950.
    PubMed     Abstract available


  134. PAWAR P, Vaishampayan S, Shah DH, Pai A, et al
    Retro-auricular endo assisted selective neck dissection (how I do it).
    Oral Oncol. 2020;110:104942.
    PubMed     Abstract available


  135. HACKMAN TG, Patel SN, Deal AM, Neil Hayes D, et al
    Novel induction therapy transoral surgery treatment paradigm with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck - Mature clinical and functional outcomes.
    Oral Oncol. 2020;110:104957.
    PubMed     Abstract available


  136. MAHAJAN A, Ahuja A, Sable N, Stambuk HE, et al
    Corrigendum to "Imaging in oral cancers: A comprehensive review" [Oral Oncol. 104 (2020) 104658].
    Oral Oncol. 2020;111:104956.
    PubMed    


  137. WICKER CA, Takiar V, Suganya R, Arnold SM, et al
    Evaluation of antioxidant network proteins as novel prognostic biomarkers for head and neck cancer patients.
    Oral Oncol. 2020;111:104949.
    PubMed     Abstract available


  138. PARK JC, Durbeck J, Boudadi K, Ho WJ, et al
    The efficacy of anti-PD-1 immune checkpoint inhibitor in nasopharyngeal carcinoma.
    Oral Oncol. 2020 Aug 10:104935. doi: 10.1016/j.oraloncology.2020.104935.
    PubMed    


  139. MOON JH, Lee SH, Koo BS, Kim JM, et al
    Slug is a novel molecular target for head and neck squamous cell carcinoma stem-like cells.
    Oral Oncol. 2020;111:104948.
    PubMed     Abstract available


  140. CHEN TC, Wu CT, Wang CP, Lou PJ, et al
    The differences of immunologic and TP53 mutant phenotypes between synchronous and metachronous head and neck cancer and esophageal cancer.
    Oral Oncol. 2020;111:104945.
    PubMed     Abstract available


  141. VAN LANSCHOT CGF, Klazen YP, de Ridder MAJ, Mast H, et al
    Depth of invasion in early stage oral cavity squamous cell carcinoma: The optimal cut-off value for elective neck dissection.
    Oral Oncol. 2020;111:104940.
    PubMed     Abstract available


  142. WANG J, Lian CL, Zheng H, Lin LE, et al
    Cognitive dysfunction in patients with nasopharyngeal carcinoma after induction chemotherapy.
    Oral Oncol. 2020;111:104921.
    PubMed     Abstract available


  143. DENARO N, Merlotti AM, Merlano MC, Russi E, et al
    Coronavirus disease 19 (COVID-19) during chemoradiation for locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).
    Oral Oncol. 2020;107:104801.
    PubMed    


  144. GALLO O, Trotta M, Orlando P, Maggiore G, et al
    SARS-CoV-2 in upper and lower airway samples of a laryngectomized patient: New insights and many lessons.
    Oral Oncol. 2020;107:104841.
    PubMed    


  145. DENARO N, Merlotti AM, Merlano MC, Russi E, et al
    Coronavirus disease 19 (COVID-19) during chemoradiation for locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).
    Oral Oncol. 2020;107:104801.
    PubMed    


  146. DENARO N, Merlotti AM, Merlano MC, Russi E, et al
    Coronavirus disease 19 (COVID-19) during chemoradiation for locally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC).
    Oral Oncol. 2020;107:104801.
    PubMed    


    July 2020
  147. ZENG YY, Xiang ZZ, He T, Liu F, et al
    The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2020;111:104924.
    PubMed     Abstract available


  148. WANG Q, Xu G, Xia Y, Zuo J, et al
    Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2020;111:104925.
    PubMed     Abstract available


  149. NEWTON H, Mcrae AB, Shanahan D
    The dangers of delaying treatment in oral cancer: A seventeenth-century perspective.
    Oral Oncol. 2020 Jul 23:104911. doi: 10.1016/j.oraloncology.2020.104911.
    PubMed    


  150. LI W, Lu H, Liu J, Liu Q, et al
    A novel nomogram to predict survival in patients with recurrent nasopharyngeal carcinoma after salvage endoscopic surgery.
    Oral Oncol. 2020;111:104922.
    PubMed     Abstract available


  151. YANG YH, Warnakulasuriya S, Yang HF, Lin LJ, et al
    Public health measures to reduce areca nut and betel quid use for control of oral cancer in Taiwan.
    Oral Oncol. 2020 Jul 22:104915. doi: 10.1016/j.oraloncology.2020.104915.
    PubMed    


  152. D'SOUZA W, Kumar A
    microRNAs in oral cancer: Moving from bench to bed as next generation medicine.
    Oral Oncol. 2020;111:104916.
    PubMed     Abstract available


  153. MARTELLI-JUNIOR H, Machado RA, Martelli DRB, Andrade MC, et al
    Oral cancer and ACE2 receptor of SARS-CoV-2.
    Oral Oncol. 2020 Jul 21:104920. doi: 10.1016/j.oraloncology.2020.104920.
    PubMed    


  154. BONOMI M, Bhateja P, Issa M, Klamer B, et al
    A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors.
    Oral Oncol. 2020;110:104900.
    PubMed     Abstract available


  155. STEPAN KO, Li MM, Kang SY, Puram SV, et al
    Molecular margins in head and neck cancer: Current techniques and future directions.
    Oral Oncol. 2020;110:104893.
    PubMed     Abstract available


  156. MCDOWELL L, So N, Keshavarzi S, Xu W, et al
    Sexual satisfaction in nasopharyngeal carcinoma survivors: Rates and determinants.
    Oral Oncol. 2020;109:104865.
    PubMed     Abstract available


  157. YANG H, Liu Y, Zhang R, Ye Y, et al
    Prognostic value of the tumor volume reduction rate after neoadjuvant chemotherapy in patients with locoregional advanced nasopharyngeal carcinoma.
    Oral Oncol. 2020;110:104897.
    PubMed     Abstract available


  158. SCHORN L, Lommen J, Sproll C, Kruskemper G, et al
    Evaluation of patient specific care needs during treatment for head and neck cancer.
    Oral Oncol. 2020;110:104898.
    PubMed     Abstract available


  159. HSU AC, Kokot NC, Eisenberg BL, Thomas JS, et al
    Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report.
    Oral Oncol. 2020 Jul 11:104899. doi: 10.1016/j.oraloncology.2020.104899.
    PubMed     Abstract available


  160. BRINKMAN D, Callanan D, O'Shea R, Jawad H, et al
    Impact of 3 mm margin on risk of recurrence and survival in oral cancer.
    Oral Oncol. 2020;110:104883.
    PubMed     Abstract available


  161. MATOS LL, Pinheiro RA, Kowalski LP
    Depth of invasion applied to oropharynx does not improve prognosis discrimination according to AJCC stage groups for oral cancer.
    Oral Oncol. 2020 Jul 9:104890. doi: 10.1016/j.oraloncology.2020.104890.
    PubMed    


  162. HUNG TM, Fan KH, Kang CJ, Huang SF, et al
    Lymph node-to-primary tumor standardized uptake value ratio on PET predicts distant metastasis in nasopharyngeal carcinoma.
    Oral Oncol. 2020;110:104756.
    PubMed     Abstract available


  163. LI X, Lee A, Cohen MA, Sherman EJ, et al
    Past, present and future of proton therapy for head and neck cancer.
    Oral Oncol. 2020;110:104879.
    PubMed     Abstract available


  164. OSAZUWA-PETERS N, Barnes JM, Megwalu U, Adjei Boakye E, et al
    State Medicaid expansion status, insurance coverage and stage at diagnosis in head and neck cancer patients.
    Oral Oncol. 2020;110:104870.
    PubMed     Abstract available


  165. TRIBIUS S, Pazdyka H, Tennstedt P, Busch CJ, et al
    Prognostic factors for lymphedema in patients with locally advanced head and neck cancer after combined radio(chemo)therapy- results of a longitudinal study.
    Oral Oncol. 2020;109:104856.
    PubMed     Abstract available


  166. CHEN G, Wu Q, Jiang H, Zhong Y, et al
    The impact of the COVID-19 pandemic on head and neck cancer patients.
    Oral Oncol. 2020 Jul 2:104881. doi: 10.1016/j.oraloncology.2020.104881.
    PubMed    


  167. BRCIC I, Gallob M, Schwantzer G, Zrnc T, et al
    Concordance of tumor infiltrating lymphocytes, PD-L1 and p16 expression in small biopsies, resection and lymph node metastases of oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;106:104719.
    PubMed     Abstract available


  168. COHEN ER, Reis IM, Gomez-Fernandez C, Smith D, et al
    CD44 and associated markers in oral rinses and tissues from oral and oropharyngeal cancer patients.
    Oral Oncol. 2020;106:104720.
    PubMed     Abstract available


  169. KISHIMOTO Y, Tateya I, Funakoshi M, Miyamoto SI, et al
    Endoscopic laryngopharyngeal surgery for hypopharyngeal lesions.
    Oral Oncol. 2020;106:104655.
    PubMed     Abstract available


  170. SEKARUTAMI SM, Gondhowiardjo S, Yuliasti R, Syarifah L, et al
    Survival of nasopharyngeal cancer in national referral hospital of Indonesia: A study on radiotherapy patients.
    Oral Oncol. 2020;106:104707.
    PubMed     Abstract available


  171. FERRARI M, Ioppi A, Schreiber A, Gualtieri T, et al
    Malignant tumors of the maxillary sinus: Prognostic impact of neurovascular invasion in a series of 138 patients.
    Oral Oncol. 2020;106:104672.
    PubMed     Abstract available


    June 2020
  172. KATSOULAKIS E, Yu Y, Apte AP, Leeman JE, et al
    Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma.
    Oral Oncol. 2020;110:104877.
    PubMed     Abstract available


  173. QUER M, Leon X, Casasayas M, Sansa A, et al
    Salvage surgery in head and neck cancer: External validation of predictors of disease-specific survival.
    Oral Oncol. 2020;109:104876.
    PubMed     Abstract available


  174. KE L, Deng Y, Xia W, Qiang M, et al
    Development of a self-constrained 3D DenseNet model in automatic detection and segmentation of nasopharyngeal carcinoma using magnetic resonance images.
    Oral Oncol. 2020;110:104862.
    PubMed     Abstract available


  175. LIU K, Lin S, Ke L, Xia W, et al
    Prognostic value and the potential role of treatment options for cervical lymph node necrosis in nasopharyngeal carcinoma.
    Oral Oncol. 2020;109:104864.
    PubMed     Abstract available


  176. LIU C, Liao L, Wu G, Yan H, et al
    Radiation-induced second primary squamous cell carcinoma of the oral cavity after radiotherapy for nasopharyngeal carcinoma.
    Oral Oncol. 2020;109:104863.
    PubMed     Abstract available


  177. BORSETTO D, Fussey J, Fabris L, Bandolin L, et al
    HCV infection and the risk of head and neck cancer: A meta-analysis.
    Oral Oncol. 2020;109:104869.
    PubMed     Abstract available


  178. VIET CT, Dierks EJ, Cheng AC, Patel AA, et al
    Transoral robotic surgery and neck dissection for HPV-positive oropharyngeal carcinoma: Importance of nodal count in survival.
    Oral Oncol. 2020;109:104770.
    PubMed     Abstract available


  179. MES SW, Brink A, Sistermans EA, Straver R, et al
    Comprehensive multiparameter genetic analysis improves circulating tumor DNA detection in head and neck cancer patients.
    Oral Oncol. 2020;109:104852.
    PubMed     Abstract available


  180. KAR A, M R A, Bhaumik U, Rao VUS, et al
    Psychological issues in head and neck cancer survivors: Need for addressal in rehabilitation.
    Oral Oncol. 2020 Jun 18:104859. doi: 10.1016/j.oraloncology.2020.104859.
    PubMed     Abstract available


  181. HAN HR, Hermann GM, Ma SJ, Iovoli AJ, et al
    Matched pair analysis to evaluate the impact of hospitalization during radiation therapy as an early marker of survival in head and neck cancer patients.
    Oral Oncol. 2020;109:104854.
    PubMed     Abstract available


  182. CHU C, Sun Y, Pan Y
    Immunotherapy is a preferred option for oral cancer patients during COVID-19 pandemic?
    Oral Oncol. 2020 Jun 15:104860. doi: 10.1016/j.oraloncology.2020.104860.
    PubMed    


  183. WOODS LT, Jasmer KJ, Munoz Forti K, Shanbhag VC, et al
    P2Y2 receptors mediate nucleotide-induced EGFR phosphorylation and stimulate proliferation and tumorigenesis of head and neck squamous cell carcinoma cell lines.
    Oral Oncol. 2020;109:104808.
    PubMed     Abstract available


  184. MAHAJAN A, Ahuja A, Sable N, Stambuk HE, et al
    Reply to letter to editor - Dr Arya's response to "Imaging in oral cancers: A comprehensive review".
    Oral Oncol. 2020 Jun 10:104847. doi: 10.1016/j.oraloncology.2020.104847.
    PubMed    


  185. LECHIEN JR, Fakhry N, Saussez S, Chiesa-Estomba CM, et al
    Surgical, clinical and functional outcomes of transoral robotic surgery for supraglottic laryngeal cancers: A systematic review.
    Oral Oncol. 2020;109:104848.
    PubMed     Abstract available


  186. LIN TY, Lan MY, Tsou HH, Ho CY, et al
    Survival impacts of different nodal characteristics and T-classification in N3 nasopharyngeal carcinoma patients.
    Oral Oncol. 2020;108:104820.
    PubMed     Abstract available


  187. GARCIA-MARTIN JM, Garcia-Pola MJ, Varela-Centelles P, Seoane-Romero JM, et al
    On the role of physicians in oral cancer diagnosis.
    Oral Oncol. 2020;108:104843.
    PubMed    


  188. ALESSANDRINI L, Franz L, Ottaviano G, Ghi MG, et al
    Prognostic role of programmed death ligand 1 (PD-L1) and the immune microenvironment in laryngeal carcinoma.
    Oral Oncol. 2020;108:104836.
    PubMed     Abstract available


  189. KAUL P, Singh MP, Pasricha R, Garg PK, et al
    Methotrexate based oral chemotherapy for advanced oral cancer during COVID-19 pandemic: Another option in the therapeutic armamentarium.
    Oral Oncol. 2020 Jun 4:104839. doi: 10.1016/j.oraloncology.2020.104839.
    PubMed    


  190. KREIMER AR, Chaturvedi AK, Alemany L, Anantharaman D, et al
    Summary from an international cancer seminar focused on human papillomavirus (HPV)-positive oropharynx cancer, convened by scientists at IARC and NCI.
    Oral Oncol. 2020;108:104736.
    PubMed     Abstract available


  191. IQBAL MS, Warner L, Paleri V, Kovarik J, et al
    De-intensification of treatment in human papilloma virus related oropharyngeal carcinoma: Patient choice still matters for de-escalation and for the COVID era.
    Oral Oncol. 2020;105:104768.
    PubMed    


  192. SASAKI CT, Hajek M, Doukas SG, Vageli DP, et al
    The role of bile reflux and its related NF-kappaB activated pathway in progression of hypopharyngeal squamous cell cancer.
    Oral Oncol. 2020;105:104668.
    PubMed     Abstract available


  193. BIGELOW EO, Seiwert TY, Fakhry C
    Deintensification of treatment for human papillomavirus-related oropharyngeal cancer: Current state and future directions.
    Oral Oncol. 2020;105:104652.
    PubMed     Abstract available


  194. JANK BJ, Kadletz L, Dunkler D, Haas M, et al
    Epithelial stem cell marker LGR6 expression identifies a low-risk subgroup in human papillomavirus positive oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;105:104657.
    PubMed     Abstract available


    May 2020
  195. FARQUHAR DR, Coniglio AJ, Masood MM, Lenze N, et al
    Evaluation of pathologic staging using number of nodes in p16-negative head and neck cancer.
    Oral Oncol. 2020;108:104800.
    PubMed     Abstract available


  196. MAZUL AL, Stepan KO, Barrett TF, Thorstad WL, et al
    Duration of radiation therapy is associated with worse survival in head and neck cancer.
    Oral Oncol. 2020;108:104819.
    PubMed     Abstract available


  197. RIVA G, Pizzo C, Fassone E, Pecorari G, et al
    Head and neck cancer surgery in COVID-19 pandemic in Northern Italy.
    Oral Oncol. 2020 May 30:104835. doi: 10.1016/j.oraloncology.2020.104835.
    PubMed    


  198. BEDDOK A, Krieger S, Castera L, Stoppa-Lyonnet D, et al
    Management of Fanconi Anemia patients with head and neck carcinoma: Diagnosis and treatment adaptation.
    Oral Oncol. 2020;108:104816.
    PubMed     Abstract available


  199. SUBRAMANIAM N, Clark JR, Goldstein D, de Almeida J, et al
    Stage pN3a in oral cancer: A redundant entity?
    Oral Oncol. 2020 May 25:104815. doi: 10.1016/j.oraloncology.2020.104815.
    PubMed    


  200. DAY D, Prawira A, Spreafico A, Waldron J, et al
    Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck.
    Oral Oncol. 2020;108:104753.
    PubMed     Abstract available


  201. YIN CH, Kang BH, Liu WS, Pan LF, et al
    New prediction tool-LIST-with improved prediction accuracy for 30-day readmission rates in patients with head and neck cancer after major cancer surgery.
    Oral Oncol. 2020;108:104772.
    PubMed     Abstract available


  202. SULTANIA M, Muduly D, Imaduddin M, Kar M, et al
    Oral Cancer Surgery and COVID pandemic - Metronomic Therapy shows a promising role while awaiting surgery.
    Oral Oncol. 2020 May 22:104814. doi: 10.1016/j.oraloncology.2020.104814.
    PubMed    


  203. CHOI SY, Lee DW, Song B, Kim SY, et al
    A rapid quantification of invasive phenotype in head and neck squamous cell carcinoma: A novel 3D pillar array system.
    Oral Oncol. 2020;108:104807.
    PubMed     Abstract available


  204. DEVARAJA K
    Surgical sequence of neck dissection and primary tumor excision could impact the locoregional recurrence rates in oral squamous cell carcinoma.
    Oral Oncol. 2020 May 21:104809. doi: 10.1016/j.oraloncology.2020.104809.
    PubMed    


  205. JOO YH, Cho KJ, Kim GJ, Kim MS, et al
    Prognostic impact of resection margin involvement in surgically managed HPV-positive tonsil cancer.
    Oral Oncol. 2020;108:104806.
    PubMed     Abstract available


  206. SU SY, Chen WT, Chiang CJ, Yang YW, et al
    Oral cancer incidence rates from 1997 to 2016 among men in Taiwan: Association between birth cohort trends and betel nut consumption.
    Oral Oncol. 2020;107:104798.
    PubMed     Abstract available


  207. ZHOU K, Li Y, Liao W, Zhang M, et al
    Pembrolizumab alone or with chemotherapy for squamous cell carcinoma of the head and neck: A cost-effectiveness analysis from Chinese perspective.
    Oral Oncol. 2020;107:104754.
    PubMed     Abstract available


  208. OU D, Wang X, Xue F, Niu X, et al
    Is nasopharyngeal carcinoma in young patients a distinct clinical entity? A single-institution case matched analysis in the era of intensity-modulated radiotherapy.
    Oral Oncol. 2020;107:104779.
    PubMed     Abstract available


  209. KAUL P, Kumar R, Singh MP, Garg PK, et al
    Baffling posterior belly of digastric muscle during neck dissection.
    Oral Oncol. 2020 May 12:104783. doi: 10.1016/j.oraloncology.2020.104783.
    PubMed    


  210. KYLMA AK, Jouhi L, Mohamed H, Randen-Brady R, et al
    In HPV-negative oropharyngeal squamous cell carcinoma, elevated toll-like receptor 2 immunoexpression may increase the risk of disease-specific mortality.
    Oral Oncol. 2020;107:104778.
    PubMed     Abstract available


  211. JAYARAJ R, Shetty S, Kumaraswamy C, Raymond G, et al
    Clinical validity and conceptual interpretation of systematic review and meta-analysis on elective neck dissection (END) versus observation for early-stage oral squamous cell carcinoma (OSCC).
    Oral Oncol. 2020 May 8:104764. doi: 10.1016/j.oraloncology.2020.104764.
    PubMed    


  212. LOCATELLO LG, Bruno C, Pietragalla M, Taverna C, et al
    A critical evaluation of computed tomography-derived depth of invasion in the preoperative assessment of oral cancer staging.
    Oral Oncol. 2020;107:104749.
    PubMed     Abstract available


  213. LEE J, Kim WC, Yoon WS, Koom WS, et al
    Reirradiation using stereotactic body radiotherapy in the management of recurrent or second primary head and neck cancer: A meta-analysis and systematic review.
    Oral Oncol. 2020;107:104757.
    PubMed     Abstract available


  214. ARAVIND S, Pandiar D, Nayanar SK, Babu S, et al
    Nodal metastasis from papillary thyroid carcinoma (PTC) with no evidence of primary tumor in the thyroid gland: Case report and literature review.
    Oral Oncol. 2020 May 6:104761. doi: 10.1016/j.oraloncology.2020.104761.
    PubMed    


  215. HALBOUB E, Al-Maweri SA, Al-Soneidar WA
    Utilization of COVID-19 testing for opportunistic screening of oral cancer.
    Oral Oncol. 2020 May 6:104775. doi: 10.1016/j.oraloncology.2020.104775.
    PubMed    


  216. VARGHESE BT
    The Kerala Model of health care delivery and its impact on Oral cancer care during the COVID 19 pandemic.
    Oral Oncol. 2020 May 3:104769. doi: 10.1016/j.oraloncology.2020.104769.
    PubMed    


  217. AL-MAWERI SA, Halboub E, Warnakulasuriya S
    Impact of COVID-19 on the early detection of oral cancer: A special emphasis on high risk populations.
    Oral Oncol. 2020 May 3:104760. doi: 10.1016/j.oraloncology.2020.104760.
    PubMed    


  218. VALENTINI V, Pucci R, Battisti A, Cassoni A, et al
    Head and neck cancer cannot wait for this pandemic to end: Risks, challenges and perspectives of oral-maxillofacial surgeon during COVID-19.
    Oral Oncol. 2020 May 1:104758. doi: 10.1016/j.oraloncology.2020.104758.
    PubMed    


  219. TSAI YF, Wang YY, Yuan SF
    Comet tail, an indicator for DNA damage or repair?: Refers to Liu et al. Oral Oncology 2020 Jan;100:104469.
    Oral Oncol. 2020;104:104624.
    PubMed    


  220. MANNELLI G, Gazzini L, Comini LV, Parrinello G, et al
    Double free flaps in oral cavity and oropharynx reconstruction: Systematic review, indications and limits.
    Oral Oncol. 2020;104:104637.
    PubMed     Abstract available


  221. CHOW VLY, Chan JYW, Cheng IKY, Chan KMK, et al
    Swallowing disorders following free jejunal flap reconstruction of circumferential pharyngeal defect: Does Botox help?
    Oral Oncol. 2020;104:104612.
    PubMed     Abstract available


    April 2020
  222. SCHROEDER L, Pring M, Ingarfield K, Pawlita M, et al
    HPV driven squamous cell head and neck cancer of unknown primary is likely to be HPV driven squamous cell oropharyngeal cancer.
    Oral Oncol. 2020;107:104721.
    PubMed     Abstract available


  223. JUNG AR, Roh JL, Kim JS, Choi SH, et al
    Post-treatment (18)F-FDG PET/CT for predicting survival and recurrence in patients with advanced-stage head and neck cancer undergoing curative surgery.
    Oral Oncol. 2020;107:104750.
    PubMed     Abstract available


  224. WEN DW, Li ZX, Chen FP, Lin L, et al
    Individualized cumulative cisplatin dose for locoregionally-advanced nasopharyngeal carcinoma patients receiving induction chemotherapy and concurrent chemoradiotherapy.
    Oral Oncol. 2020;107:104675.
    PubMed     Abstract available


  225. ARYA S
    Letter to Editor in response to "Imaging in oral cancers: A comprehensive review. Oral Oncology 2020, 21;104:104658. Mahajan A, Ahuja A, Sable N, Stambuk HE".
    Oral Oncol. 2020 Apr 27:104735. doi: 10.1016/j.oraloncology.2020.104735.
    PubMed    


  226. LEONEL ACLDS, Martelli-Junior H, Bonan PRF, Kowalski LP, et al
    COVID-19, head and neck cancer, and the need of training of health students and practitioners regarding to tobacco control and patient counseling.
    Oral Oncol. 2020 Apr 24:104739. doi: 10.1016/j.oraloncology.2020.104739.
    PubMed    


  227. CHAVES ALF, Castro AF, Marta GN, Junior GC, et al
    Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic.
    Oral Oncol. 2020;107:104734.
    PubMed    


  228. PIETROBON G, Tagliabue M, Chu F, De Berardinis R, et al
    COVID alias challenge to onco-rehabilitation and to viable indications and decisions: Cues from an Italian COVID+ oral cancer patient.
    Oral Oncol. 2020 Apr 24:104745. doi: 10.1016/j.oraloncology.2020.104745.
    PubMed    


  229. CARSUZAA F, Gorphe P, Vergez S, Malard O, et al
    Consensus on resectability in N3 head and neck squamous cell carcinomas: GETTEC recommendations.
    Oral Oncol. 2020;106:104733.
    PubMed     Abstract available


  230. YUEN E, Fote G, Horwich P, Nguyen SA, et al
    Head and neck cancer care in the COVID-19 pandemic: A brief update.
    Oral Oncol. 2020 Apr 23:104738. doi: 10.1016/j.oraloncology.2020.104738.
    PubMed    


  231. JAYARAJ R, Shetty S, Kumaraswamy C, Raymond G, et al
    Clinical validity of clinicopathological and prognostic significance of circulating tumor cells in head and neck squamous cell carcinoma.
    Oral Oncol. 2020 Apr 21:104727. doi: 10.1016/j.oraloncology.2020.104727.
    PubMed    


  232. QIN G, Rai R, Zhang R, Su Y, et al
    Feasibility and efficiency of double-agent versus single-agent concurrent chemoradiotherapy in patients with nasopharyngeal carcinoma.
    Oral Oncol. 2020;106:104704.
    PubMed     Abstract available


  233. KUMAR N, Deo SVS, Mishra D
    Distant recurrence of oral carcinoma at tracheostomy site: A rare presentation.
    Oral Oncol. 2020 Apr 20:104692. doi: 10.1016/j.oraloncology.2020.104692.
    PubMed    


  234. LI B, Ren M, Zhou X, Han Q, et al
    Targeting tumor-associated macrophages in head and neck squamous cell carcinoma.
    Oral Oncol. 2020;106:104723.
    PubMed     Abstract available


  235. NAGAO T, Warnakulasuriya S
    Screening for oral cancer: Future prospects, research and policy development for Asia.
    Oral Oncol. 2020;105:104632.
    PubMed     Abstract available


  236. FERNANDES DT, Prado-Ribeiro AC, Markman RL, Morais K, et al
    The impact of an educational video about radiotherapy and its toxicities in head and neck cancer patients. Evaluation of patients' understanding, anxiety, depression, and quality of life.
    Oral Oncol. 2020;106:104712.
    PubMed     Abstract available


  237. DA CRUZ PEREZ DE, Passos KKM, Machado RA, Martelli-Junior H, et al
    Continuing education in oral cancer during coronavirus disease 2019 (covid-19) outbreak.
    Oral Oncol. 2020 Apr 16:104713. doi: 10.1016/j.oraloncology.2020.104713.
    PubMed    


  238. SUN XS, Liang YJ, Jia GD, Liu SL, et al
    Establishment of a prognostic nomogram to identify optimal candidates for local treatment among patients with local recurrent nasopharyngeal carcinoma.
    Oral Oncol. 2020;106:104711.
    PubMed     Abstract available


  239. TANG SQ, Xu C, Wang XS, Tang LL, et al
    Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: A propensity score-matched analysis.
    Oral Oncol. 2020;105:104686.
    PubMed     Abstract available


  240. MOLONY P, Werner R, Martin C, Callanan D, et al
    The role of tumour morphology in assigning HPV status in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;105:104670.
    PubMed     Abstract available


  241. DHAR H, Vaish R, D'Cruz AK, Vaish R, et al
    Management of locally advanced oral cancers.
    Oral Oncol. 2020;105:104662.
    PubMed     Abstract available


  242. SALARI A, Shirkhoda M
    COVID-19 pandemic & head and neck cancer patients management: The role of virtual multidisciplinary team meetings.
    Oral Oncol. 2020 Apr 8:104693. doi: 10.1016/j.oraloncology.2020.104693.
    PubMed    


  243. KUMAR N, Bhoriwal S, Mishra D, Deo SVS, et al
    Cutaneous ulceration: A sign of methotrexate toxicity in oral cancer patient.
    Oral Oncol. 2020 Apr 6:104671. doi: 10.1016/j.oraloncology.2020.104671.
    PubMed    


  244. OLIVA M, Huang SH, Taylor R, Su J, et al
    Impact of cumulative cisplatin dose and adjuvant chemotherapy in locally-advanced nasopharyngeal carcinoma treated with definitive chemoradiotherapy.
    Oral Oncol. 2020;105:104666.
    PubMed     Abstract available


  245. KACEW AJ, Harris EJ, Lorch JH, Schoenfeld JD, et al
    Chemotherapy after immune checkpoint blockade in patients with recurrent, metastatic squamous cell carcinoma of the head and neck.
    Oral Oncol. 2020;105:104676.
    PubMed     Abstract available


  246. PATEL RR, Ludmir EB, Augustyn A, Zaorsky NG, et al
    De-intensification of therapy in human papillomavirus associated oropharyngeal cancer: A systematic review of prospective trials.
    Oral Oncol. 2020;103:104608.
    PubMed     Abstract available


  247. DE VIRGILIO A, Costantino A, Mercante G, Di Maio P, et al
    Trans-oral robotic surgery in the management of parapharyngeal space tumors: A systematic review.
    Oral Oncol. 2020;103:104581.
    PubMed     Abstract available


  248. CANAVAN JF, Harr BA, Bodmann JW, Reddy CA, et al
    Impact of routine surveillance imaging on detecting recurrence in human papillomavirus associated oropharyngeal cancer.
    Oral Oncol. 2020;103:104585.
    PubMed     Abstract available


  249. FARLOW JL, Rosko AJ, Spector ME
    Treatment of end-stage pharyngeal strictures after laryngectomy with fasciocutaneous microvascular reconstruction.
    Oral Oncol. 2020;103:104556.
    PubMed     Abstract available


  250. CABEZAS-CAMARERO S, Perez-Alfayate R, Puebla F, Cabrera-Martin MN, et al
    Increased clinical and plasma EBV DNA responses to platinum-gemcitabine after nivolumab in patients with heavily platinum-pretreated nasopharyngeal cancer.
    Oral Oncol. 2020;103:104527.
    PubMed    


    March 2020
  251. OH LJ, Phan K, Kim SW, Low TH, et al
    Elective neck dissection versus observation for early-stage oral squamous cell carcinoma: Systematic review and meta-analysis.
    Oral Oncol. 2020;105:104661.
    PubMed     Abstract available


  252. MAHAJAN A, Ahuja A, Sable N, Stambuk HE, et al
    Imaging in oral cancers: A comprehensive overview of imaging findings for staging and treatment planning.
    Oral Oncol. 2020;104:104658.
    PubMed     Abstract available


  253. ZANONI DK, Patel SG
    New AJCC: How does it impact oral cancers?
    Oral Oncol. 2020;104:104607.
    PubMed     Abstract available


  254. DHARMAWARDANA N, Woods C, Watson DI, Yazbeck R, et al
    A review of breath analysis techniques in head and neck cancer.
    Oral Oncol. 2020;104:104654.
    PubMed     Abstract available


  255. HEGDE PS, Aanya A, Joshna BM, Thakur S, et al
    Gustatory dysfunction in non oral irradiation for head and neck cancers.
    Oral Oncol. 2020 Mar 16:104642. doi: 10.1016/j.oraloncology.2020.104642.
    PubMed    


  256. WANG BC, Cao RB, Fu C, Chen WB, et al
    The efficacy and safety of PD-1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2020;104:104640.
    PubMed     Abstract available


  257. XUN Y, Cao Q, Zhang J, Guan B, et al
    Clinicopathological and prognostic significance of circulating tumor cells in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2020;104:104638.
    PubMed     Abstract available


  258. FAN D, Kang JJ, Fan M, Wang H, et al
    Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers.
    Oral Oncol. 2020;104:104641.
    PubMed     Abstract available


  259. SZTURZ P, Vermorken JB
    Overcoming frailty in recurrent and metastatic head and neck cancer.
    Oral Oncol. 2020 Mar 11:104636. doi: 10.1016/j.oraloncology.2020.104636.
    PubMed    


  260. GALOT R, van Marcke C, Helaers R, Mendola A, et al
    Liquid biopsy for mutational profiling of locoregional recurrent and/or metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2020;104:104631.
    PubMed     Abstract available


  261. LIN HC, Chan SC, Cheng NM, Liao CT, et al
    Pretreatment (18)F-FDG PET/CT texture parameters provide complementary information to Epstein-Barr virus DNA titers in patients with metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2020;104:104628.
    PubMed     Abstract available


  262. WU A, Li Y, Qi M, Lu X, et al
    Dosiomics improves prediction of locoregional recurrence for intensity modulated radiotherapy treated head and neck cancer cases.
    Oral Oncol. 2020;104:104625.
    PubMed     Abstract available


  263. LIOU AK, Soon G, Tan L, Peng Y, et al
    Elevated IL18 levels in Nasopharyngeal carcinoma induced PD-1 expression on NK cells in TILS leading to poor prognosis.
    Oral Oncol. 2020;104:104616.
    PubMed     Abstract available


  264. DIGONNET A, Dekeyser C, Quiriny M, Willemse E, et al
    NIR Infrared imaging after peritumoral injection of indocyanine green to guide lymph node dissection in head and neck squamous cell carcinoma: A pilot feasibility study.
    Oral Oncol. 2020 Mar 6:104621. doi: 10.1016/j.oraloncology.2020.104621.
    PubMed    


  265. KARMAKAR S, Kar A, Thakur S, Rao VUS, et al
    Periodontitis and oral Cancer-A striking link.
    Oral Oncol. 2020 Mar 5:104630. doi: 10.1016/j.oraloncology.2020.104630.
    PubMed     Abstract available


  266. LOPEZ-CEDRUN JL, Varela-Centelles P, Otero-Rico A, Vazquez-Mahia I, et al
    Overall time interval ("Total diagnostic delay") and mortality in symptomatic oral cancer: A U-shaped association.
    Oral Oncol. 2020;104:104626.
    PubMed     Abstract available


  267. ECONOMOPOULOU P, Nicolatou-Galitis O, Kotsantis I, Psyrri A, et al
    Nivolumab-related lichen planus of the lip in a patient with head and neck cancer.
    Oral Oncol. 2020 Mar 3:104623. doi: 10.1016/j.oraloncology.2020.104623.
    PubMed     Abstract available


  268. MAZUL AL, Colditz GA, Zevallos JP
    Factors associated with HPV testing in oropharyngeal cancer in the National Cancer Data Base from 2013 to 2015.
    Oral Oncol. 2020;104:104609.
    PubMed     Abstract available


  269. SANDULACHE VC, Lei YL, Heasley LE, Chang M, et al
    Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting.
    Oral Oncol. 2020;102:104440.
    PubMed    


    February 2020
  270. GREANEY-DAVIES FST, Risk JM, Robinson M, Liloglou T, et al
    Essential characterisation of human papillomavirus positive head and neck cancer cell lines.
    Oral Oncol. 2020;103:104613.
    PubMed     Abstract available


  271. CURY SS, Lapa RML, de Mello JBH, Marchi FA, et al
    Increased DSG2 plasmatic levels identified by transcriptomic-based secretome analysis is a potential prognostic biomarker in laryngeal carcinoma.
    Oral Oncol. 2020;103:104592.
    PubMed     Abstract available


  272. WU Q, Liao W, Huang J, Zhang P, et al
    Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2020;103:104588.
    PubMed     Abstract available


  273. DE LIMA VHS, de Oliveira-Neto OB, da Hora Sales PH, da Silva Torres T, et al
    Effectiveness of low-level laser therapy for oral mucositis prevention in patients undergoing chemoradiotherapy for the treatment of head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2020;102:104524.
    PubMed     Abstract available


  274. NIEBERLER M, Stimmer H, Rasthofer D, Nentwig K, et al
    Defining secure surgical bone margins in head and neck squamous cell carcinomas: The diagnostic impact of intraoperative cytological assessment of bone resection margins compared with preoperative imaging.
    Oral Oncol. 2020;102:104579.
    PubMed     Abstract available


  275. CHANG H, Tao YL, Ye WJ, Xiao WW, et al
    Regular aspirin intake and prognosis of TxN2-3M0 nasopharyngeal carcinoma: A cohort study based on propensity score matching.
    Oral Oncol. 2020;103:104589.
    PubMed     Abstract available


  276. LI Z, Liu FY, Kirkwood KL
    The p38/MKP-1 signaling axis in oral cancer: Impact of tumor-associated macrophages.
    Oral Oncol. 2020;103:104591.
    PubMed     Abstract available


  277. YIN X, Shan C, Wang J, Zhang H, et al
    Factors associated with the quality of life for hospitalized patients with HPV-associated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;103:104590.
    PubMed     Abstract available


  278. TADA H, Takahashi H, Kuwabara-Yokobori Y, Shino M, et al
    Molecular profiling of circulating tumor cells predicts clinical outcome in head and neck squamous cell carcinoma.
    Oral Oncol. 2020;102:104558.
    PubMed     Abstract available


  279. GEIGER JL, Adelstein DJ
    Chemotherapy in the definitive management of oral cancers: Where do we stand today?
    Oral Oncol. 2020;102:104584.
    PubMed     Abstract available


  280. VAN BEEK FE, Jansen F, Mak L, Lissenberg-Witte BI, et al
    The course of symptoms of anxiety and depression from time of diagnosis up to 2 years follow-up in head and neck cancer patients treated with primary (chemo)radiation.
    Oral Oncol. 2020;102:104576.
    PubMed     Abstract available


  281. JAYARAJ R, Kumarasamy C, Sabarimurugan S, Madhav MR, et al
    Conceptual interpretation of findings on systematic review and meta-analysis of altered-fractionation radiotherapy improves local control in the early-stage glottic carcinoma.
    Oral Oncol. 2020;101:104319.
    PubMed    


  282. FAKHRY C, Waterboer T, Westra WH, Rooper LM, et al
    Distinct biomarker and behavioral profiles of human papillomavirus-related oropharynx cancer patients by age.
    Oral Oncol. 2020;101:104522.
    PubMed     Abstract available


  283. WANG Z, Qu Y, Wang K, Wu R, et al
    The value of preoperative radiotherapy in the treatment of locally advanced nasal cavity and paranasal sinus squamous cell carcinoma: A single institutional experience.
    Oral Oncol. 2020;101:104512.
    PubMed     Abstract available


  284. CHARGI N, Bril SI, Swartz JE, Wegner I, et al
    Skeletal muscle mass is an imaging biomarker for decreased survival in patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;101:104519.
    PubMed     Abstract available


  285. SATO K, Ono T, Sato F, Kawahara A, et al
    Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma.
    Oral Oncol. 2020;101:104366.
    PubMed     Abstract available


    January 2020
  286. STEPHENS SJ, Chino F, Williamson H, Niedzwiecki D, et al
    Evaluating for disparities in place of death for head and neck cancer patients in the United States utilizing the CDC WONDER database.
    Oral Oncol. 2020;102:104555.
    PubMed     Abstract available


  287. PEIGNE L, Godey F, Le Gallo M, Le Gall F, et al
    One-step nucleic acid amplification for detecting lymph node metastasis of head and neck squamous cell carcinoma.
    Oral Oncol. 2020;102:104553.
    PubMed     Abstract available


  288. HORN D, Zittel S, Moratin J, Metzger K, et al
    Prospective feasibility analysis of salvage surgery in recurrent oral cancer in terms of quality of life.
    Oral Oncol. 2020;102:104580.
    PubMed     Abstract available


  289. SHARMA N, Fagan J, Wallace M, Joubert E, et al
    Prioritisation of research topics for head and neck cancer in Africa - Report of the International Collaboration On Improving Cancer outcomes in low and middle income countries - ICOnIC Africa.
    Oral Oncol. 2020 Jan 21:104503. doi: 10.1016/j.oraloncology.2019.104503.
    PubMed    


  290. GRUNWALD V, Chirovsky D, Cheung WY, Bertolini F, et al
    Global treatment patterns and outcomes among patients with recurrent and/or metastatic head and neck squamous cell carcinoma: Results of the GLANCE H&N study.
    Oral Oncol. 2020;102:104526.
    PubMed     Abstract available


  291. LOPEZ F, Fernandez-Vanes L, Garcia-Cabo P, Grilli G, et al
    Selective neck dissection in the treatment of head and neck squamous cell carcinoma patients with a clinically positive neck.
    Oral Oncol. 2020;102:104565.
    PubMed     Abstract available


  292. STORDEUR S, Schillemans V, Savoye I, Vanschoenbeek K, et al
    Comorbidity in head and neck cancer: Is it associated with therapeutic delay, post-treatment mortality and survival in a population-based study?
    Oral Oncol. 2020;102:104561.
    PubMed     Abstract available


  293. HUANG SH, Hahn E, Chiosea SI, Xu ZY, et al
    The role of adjuvant (chemo-)radiotherapy in oral cancers in the contemporary era.
    Oral Oncol. 2020;102:104563.
    PubMed     Abstract available


  294. VAISH R, Shah S, Chaukar D
    Prognostic significance of surgical margins after transoral laser microsurgery for early-stage glottic cancer.
    Oral Oncol. 2020;100:104511.
    PubMed    


    December 2019
  295. ANSARI E, Chargi N, van Gemert JTM, van Es RJJ, et al
    Low skeletal muscle mass is a strong predictive factor for surgical complications and a prognostic factor in oral cancer patients undergoing mandibular reconstruction with a free fibula flap.
    Oral Oncol. 2019;101:104530.
    PubMed     Abstract available


  296. BEELER WH, Bellile EL, Casper KA, Jaworski E, et al
    Patient-reported financial toxicity and adverse medical consequences in head and neck cancer.
    Oral Oncol. 2019;101:104521.
    PubMed     Abstract available


  297. BLACK M, Ghasemi F, Sun RX, Stecho W, et al
    Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer.
    Oral Oncol. 2019;101:104529.
    PubMed     Abstract available


  298. PESTANA RC, Becnel M, Rubin ML, Torman DK, et al
    Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2019;101:104523.
    PubMed     Abstract available


  299. MATSUO M, Yasumatsu R, Masuda M, Toh S, et al
    Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
    Oral Oncol. 2019;101:104525.
    PubMed     Abstract available


  300. AMPIL F, Previgliano C, Porter C, Richards T, et al
    Metachronous mediastinal and lung metastases from head and neck cancer: A case series, literature review and considerations for treatment.
    Oral Oncol. 2019 Dec 17:104518. doi: 10.1016/j.oraloncology.2019.104518.
    PubMed     Abstract available


  301. AANYA A, Hegde PS, Fernando CA, Thakur S, et al
    Intolerance to pungent spices among patients receiving radiation and chemotherapy for head and neck cancers.
    Oral Oncol. 2019 Dec 16:104517. doi: 10.1016/j.oraloncology.2019.104517.
    PubMed    


  302. PAN XB, Li L, Qu S, Chen L, et al
    The efficacy of chemotherapy in survival of stage II nasopharyngeal carcinoma.
    Oral Oncol. 2019;101:104520.
    PubMed     Abstract available


  303. YOUNG RJ, Bressel M, Porceddu S, Cernelc J, et al
    Validation and characterisation of prognostically significant PD-L1(+) immune cells in HPV+ oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2019;101:104516.
    PubMed     Abstract available


  304. DOUMAS S, Foukas PG, Economopoulou P, Kotsantis I, et al
    Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer.
    Oral Oncol. 2019;100:104477.
    PubMed     Abstract available


  305. HOLTZMAN AL, Mendenhall WM
    High-dose conformal proton therapy for clinical perineural invasion in cutaneous head and neck cancer.
    Oral Oncol. 2019;100:104486.
    PubMed     Abstract available


  306. MOWERY A, Conlin M, Clayburgh D
    Increased risk of head and neck cancer in Agent Orange exposed Vietnam Era veterans.
    Oral Oncol. 2019;100:104483.
    PubMed     Abstract available


    November 2019
  307. PANTVAIDYA G, Rao K, D'Cruz A
    Management of the neck in oral cancers.
    Oral Oncol. 2019;100:104476.
    PubMed     Abstract available


  308. SUN XS, Li XY, Xiao BB, Liu SL, et al
    Establishment and validation of a nomogram for predicting the benefit of concurrent chemotherapy in stage II nasopharyngeal carcinoma: A study based on a phase III randomized clinical trial with 10-year follow-up.
    Oral Oncol. 2019;100:104490.
    PubMed     Abstract available


  309. MOORE C, McLister C, Cardwell C, O'Neill C, et al
    Dental caries following radiotherapy for head and neck cancer: A systematic review.
    Oral Oncol. 2019;100:104484.
    PubMed     Abstract available


  310. SEMRAU S, Schmidt D, Hecht M, Haderlein M, et al
    Classification of three prognostically different groups of head and neck cancer patients based on their metabolic response to induction chemotherapy (IC-1).
    Oral Oncol. 2019;100:104479.
    PubMed     Abstract available


  311. STROBER W, Shishido S, Wood B, Lewis JS Jr, et al
    Two for the price of one: Prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck Cancers.
    Oral Oncol. 2019;100:104475.
    PubMed     Abstract available


  312. TAYYABA, Akram N, Rehman FU
    A new wave of oral cancer epidemic among youth in Pakistan.
    Oral Oncol. 2019 Nov 20:104480. doi: 10.1016/j.oraloncology.2019.104480.
    PubMed    


  313. XUE F, Ou D, Ou X, Zhou X, et al
    Prognostic efficacy of extensive invasion of primary tumor volume for T3-4 nasopharyngeal carcinoma receiving intensity-modulated radiotherapy.
    Oral Oncol. 2019;100:104478.
    PubMed     Abstract available


  314. LIU C, Liao K, Gross N, Wang Z, et al
    Homologous recombination enhances radioresistance in hypopharyngeal cancer cell line by targeting DNA damage response.
    Oral Oncol. 2019;100:104469.
    PubMed     Abstract available


  315. LU DJ, Luu M, Nguyen AT, Scher KS, et al
    Survival outcomes with concomitant chemoradiotherapy in older adults with oropharyngeal carcinoma in an era of increasing human papillomavirus (HPV) prevalence.
    Oral Oncol. 2019;99:104472.
    PubMed     Abstract available


  316. QI Z, Barrett T, Parikh AS, Tirosh I, et al
    Single-cell sequencing and its applications in head and neck cancer.
    Oral Oncol. 2019;99:104441.
    PubMed     Abstract available


  317. ORLANDI E, Iacovelli NA, Tombolini V, Rancati T, et al
    Potential role of microbiome in oncogenesis, outcome prediction and therapeutic targeting for head and neck cancer.
    Oral Oncol. 2019;99:104453.
    PubMed     Abstract available


  318. CRAMER JD, Burtness B, Ferris RL
    Immunotherapy for head and neck cancer: Recent advances and future directions.
    Oral Oncol. 2019;99:104460.
    PubMed     Abstract available


  319. SEKIDO K, Tomihara K, Tachinami H, Heshiki W, et al
    Alterations in composition of immune cells and impairment of anti-tumor immune response in aged oral cancer-bearing mice.
    Oral Oncol. 2019;99:104462.
    PubMed     Abstract available


    October 2019
  320. OIKAWA Y, Michi Y, Tsushima F, Tomioka H, et al
    Management of retropharyngeal lymph node metastasis in oral cancer.
    Oral Oncol. 2019;99:104471.
    PubMed     Abstract available


  321. LU T, Hu Y, Xiao Y, Guo Q, et al
    Prognostic value of radiologic extranodal extension and its potential role in future N classification for nasopharyngeal carcinoma.
    Oral Oncol. 2019;99:104438.
    PubMed     Abstract available


  322. ALLEN-AYODABO CO, Eskander A, Davis LE, Zhao H, et al
    Symptom burden among head and neck cancer patients in the first year after diagnosis: Association with primary treatment modality.
    Oral Oncol. 2019;99:104434.
    PubMed     Abstract available


  323. MICCIO JA, Verma V, Kelly J, Kann BH, et al
    Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition.
    Oral Oncol. 2019;99:104447.
    PubMed     Abstract available


  324. WU LR, Zhang XM, Xie XD, Lu Y, et al
    Validation of the 8th edition of AJCC/UICC staging system for nasopharyngeal carcinoma: Results from a non-endemic cohort with 10-year follow-up.
    Oral Oncol. 2019;98:141-146.
    PubMed     Abstract available


    September 2019
  325. LI M, Chen H, Wu T
    LIN28: A cancer stem cell promoter for immunotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2019;98:92-95.
    PubMed     Abstract available


  326. YANG K, Tian J, Zhang B, Li M, et al
    A multidimensional nomogram combining overall stage, dose volume histogram parameters and radiomics to predict progression-free survival in patients with locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2019;98:85-91.
    PubMed     Abstract available


  327. HAAPANIEMI A, Makitie A, Kekolahti P, Ryynanen OP, et al
    A preliminary Bayesian network model to identify factors associated with treatment outcome in T2 and T3 laryngeal carcinoma.
    Oral Oncol. 2019 Sep 25. pii: S1368-8375(19)30306.
    PubMed    


  328. DENG J, He Y, Sun XS, Li JM, et al
    Construction of a comprehensive nutritional index and its correlation with quality of life and survival in patients with nasopharyngeal carcinoma undergoing IMRT: A prospective study.
    Oral Oncol. 2019;98:62-68.
    PubMed     Abstract available


  329. DE MARCHI P, Melendez ME, Laus AC, Kuhlmann PA, et al
    The role of single-nucleotide polymorphism (SNPs) in toxicity of induction chemotherapy based on cisplatin and paclitaxel in patients with advanced head and neck cancer.
    Oral Oncol. 2019;98:48-52.
    PubMed     Abstract available


  330. VAN HARTEN AM, Poell JB, Buijze M, Brink A, et al
    Characterization of a head and neck cancer-derived cell line panel confirms the distinct TP53-proficient copy number-silent subclass.
    Oral Oncol. 2019;98:53-61.
    PubMed     Abstract available


  331. DIONISI F, Fiorica F, D'Angelo E, Maddalo M, et al
    Organs at risk's tolerance and dose limits for head and neck cancer re-irradiation: A literature review.
    Oral Oncol. 2019;98:35-47.
    PubMed     Abstract available


  332. SANFORD NN, Hwang WL, Pike LRG, Lam AC, et al
    Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study: Trimodality therapy for HPV+OPC.
    Oral Oncol. 2019;98:28-34.
    PubMed     Abstract available


  333. LIN C, Puram SV, Bulbul MG, Sethi RK, et al
    Elective neck dissection for salvage laryngectomy: A systematic review and meta-analysis.
    Oral Oncol. 2019;96:97-104.
    PubMed     Abstract available


  334. JAJODIA A, Aggarwal D, Chaturvedi AK, Rao A, et al
    Value of diffusion MR imaging in differentiation of recurrent head and neck malignancies from post treatment changes.
    Oral Oncol. 2019;96:89-96.
    PubMed     Abstract available


  335. SALOURA V, Izumchenko E, Zuo Z, Bao R, et al
    Immune profiles in primary squamous cell carcinoma of the head and neck.
    Oral Oncol. 2019;96:77-88.
    PubMed     Abstract available


  336. SABA NF, Blumenschein G Jr, Guigay J, Licitra L, et al
    Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.
    Oral Oncol. 2019;96:7-14.
    PubMed     Abstract available


  337. MOON JH, Rho YS, Lee SH, Koo BS, et al
    Role of integrin beta1 as a biomarker of stemness in head and neck squamous cell carcinoma.
    Oral Oncol. 2019;96:34-41.
    PubMed     Abstract available


  338. CHUNG CS, Lo WC, Chen KC, Lin CL, et al
    Clinical benefits from endoscopy screening of esophageal second primary tumor for head and neck cancer patients: Analysis of a hospital-based registry.
    Oral Oncol. 2019;96:27-33.
    PubMed     Abstract available


  339. DEGRAAFF LH, Platek AJ, Iovoli AJ, Wooten KE, et al
    The effect of time between diagnosis and initiation of treatment on outcomes in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2019;96:148-152.
    PubMed     Abstract available


  340. FADEN DL, Ding F, Lin Y, Zhai S, et al
    APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
    Oral Oncol. 2019;96:140-147.
    PubMed     Abstract available


  341. YANG LL, Mao L, Wu H, Chen L, et al
    pDC depletion induced by CD317 blockade drives the antitumor immune response in head and neck squamous cell carcinoma.
    Oral Oncol. 2019;96:131-139.
    PubMed     Abstract available


  342. YAP T, Seers C, Koo K, Cheng L, et al
    Non-invasive screening of a microRNA-based dysregulation signature in oral cancer and oral potentially malignant disorders.
    Oral Oncol. 2019;96:113-120.
    PubMed     Abstract available


  343. HAM JC, van Herpen CML, Driessen CML, van der Graaf WTA, et al
    Health-related quality of life of patients treated with chemoradiotherapy plus or minus prophylactic antibiotics to reduce the number of pneumonias for locally advanced head and neck cancer, the PANTAP study.
    Oral Oncol. 2019;96:105-112.
    PubMed     Abstract available


  344. GRONHOJ C, Kronberg Jakobsen K, Kjaer E, Friborg J, et al
    Comorbidity in HPV+ and HPV- oropharyngeal cancer patients: A population-based, case-control study.
    Oral Oncol. 2019;96:1-6.
    PubMed     Abstract available


    August 2019
  345. JAYARAJ R, Madhav MR, Sabarimurugan S, Kumarasamy C, et al
    Key approaches to interpret the findings of a meta-analysis on role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery.
    Oral Oncol. 2019 Aug 30. pii: S1368-8375(19)30296.
    PubMed    


  346. VISHAL RAO US, Shetty SS, Kudpaje A, Rao GA, et al
    (i) TNM staging for head and neck cancers.
    Oral Oncol. 2019 Aug 27. pii: S1368-8375(19)30292.
    PubMed    


  347. HADDAD R, Guigay J, Keilholz U, Clement PM, et al
    Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
    Oral Oncol. 2019;97:82-91.
    PubMed     Abstract available


  348. SHARMA M, Radhakrishnan R
    A two-way relationship between the head and neck cancer and esophageal cancer.
    Oral Oncol. 2019 Aug 20. pii: S1368-8375(19)30290.
    PubMed    


  349. GIULIANI J, Bonetti A
    Immune-checkpoint inhibitors in head and neck squamous cell carcinoma: cost-efficacy in second-line treatment based on programmed death-ligand 1 (PD-L1) level.
    Oral Oncol. 2019 Aug 17. pii: S1368-8375(19)30286.
    PubMed    


  350. FAKURNEJAD S, van Keulen S, Nishio N, Engelen M, et al
    Fluorescence molecular imaging for identification of high-grade dysplasia in patients with head and neck cancer.
    Oral Oncol. 2019;97:50-55.
    PubMed     Abstract available


  351. ZHU J, Duan B, Shi H, Li Y, et al
    Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2019;97:37-43.
    PubMed     Abstract available


  352. SUN XS, Lin C, Liang YJ, Chen QY, et al
    Role of zoledronic acid in nasopharyngeal carcinoma patients with bone-only metastasis at diagnosis.
    Oral Oncol. 2019;97:31-36.
    PubMed     Abstract available


  353. IGANEJ S, Beard BW, Chen J, Buchschacher GL Jr, et al
    Triweekly carboplatin as a potential de-intensification agent in concurrent chemoradiation for early-stage HPV-associated oropharyngeal cancer.
    Oral Oncol. 2019;97:18-22.
    PubMed     Abstract available


  354. JUNG AR, Roh JL, Kim JS, Choi SH, et al
    Efficacy of head and neck computed tomography for skeletal muscle mass estimation in patients with head and neck cancer.
    Oral Oncol. 2019;95:95-99.
    PubMed     Abstract available


  355. DONG Y, Ridge JA, Ebersole B, Li T, et al
    Incidence and outcomes of radiation-induced late cranial neuropathy in 10-year survivors of head and neck cancer.
    Oral Oncol. 2019;95:59-64.
    PubMed     Abstract available


  356. LEONARD BC, Lee ED, Bhola NE, Li H, et al
    ATR inhibition sensitizes HPV(-) and HPV(+) head and neck squamous cell carcinoma to cisplatin.
    Oral Oncol. 2019;95:35-42.
    PubMed     Abstract available


  357. BLAKAJ A, Bonomi M, Gamez ME, Blakaj DM, et al
    Oral mucositis in head and neck cancer: Evidence-based management and review of clinical trial data.
    Oral Oncol. 2019;95:29-34.
    PubMed     Abstract available


  358. CHEN YF, Chang KW, Yang IT, Tu HF, et al
    Establishment of syngeneic murine model for oral cancer therapy.
    Oral Oncol. 2019;95:194-201.
    PubMed     Abstract available


  359. MADY LJ, Lyu L, Owoc MS, Peddada SD, et al
    Understanding financial toxicity in head and neck cancer survivors.
    Oral Oncol. 2019;95:187-193.
    PubMed     Abstract available


  360. ZHAI TT, Langendijk JA, van Dijk LV, Halmos GB, et al
    The prognostic value of CT-based image-biomarkers for head and neck cancer patients treated with definitive (chemo-)radiation.
    Oral Oncol. 2019;95:178-186.
    PubMed     Abstract available


  361. GAU M, Karabajakian A, Reverdy T, Neidhardt EM, et al
    Induction chemotherapy in head and neck cancers: Results and controversies.
    Oral Oncol. 2019;95:164-169.
    PubMed     Abstract available


  362. ZHANG Y, Zhang ZC, Li WF, Liu X, et al
    Prognosis and staging of parotid lymph node metastasis in nasopharyngeal carcinoma: An analysis in 10,126 patients.
    Oral Oncol. 2019;95:150-156.
    PubMed     Abstract available


  363. PARK SJ, Ye W, Xiao R, Silvin C, et al
    Cisplatin and oxaliplatin induce similar immunogenic changes in preclinical models of head and neck cancer.
    Oral Oncol. 2019;95:127-135.
    PubMed     Abstract available


  364. BARBOSA DA SILVA JL, Doty RL, Miyazaki JVMK, Borges R, et al
    Gustatory disturbances occur in patients with head and neck cancer who undergo radiotherapy not directed to the oral cavity.
    Oral Oncol. 2019;95:115-119.
    PubMed     Abstract available


  365. DAUZIER E, Lacas B, Blanchard P, Le QT, et al
    Role of chemotherapy in 5000 patients with head and neck cancer treated by curative surgery: A subgroup analysis of the meta-analysis of chemotherapy in head and neck cancer.
    Oral Oncol. 2019;95:106-114.
    PubMed     Abstract available


  366. SALUJA TS, Iyer J, Singh SK
    Leiomyosarcoma: Prognostic outline of a rare head and neck malignancy.
    Oral Oncol. 2019;95:100-105.
    PubMed     Abstract available


  367. ARGYRIS PP, Slama Z, Malz C, Koutlas IG, et al
    Intracellular calprotectin (S100A8/A9) controls epithelial differentiation and caspase-mediated cleavage of EGFR in head and neck squamous cell carcinoma.
    Oral Oncol. 2019;95:1-10.
    PubMed     Abstract available


  368. LAURITANO D, Oberti L, Gabrione F, Lucchese A, et al
    Liquid biopsy in head and neck squamous cell carcinoma: Prognostic significance of circulating tumor cells and circulating tumor DNA. A systematic review.
    Oral Oncol. 2019;97:7-17.
    PubMed    


  369. BHATTASALI O, Ryoo JJ, Thompson LDR, Abdalla IA, et al
    Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
    Oral Oncol. 2019;95:74-78.
    PubMed     Abstract available


  370. MISIUKIEWICZ K, Gupta V, Miles BA, Bakst R, et al
    Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: The Quarterback trial.
    Oral Oncol. 2019;95:170-177.
    PubMed     Abstract available


  371. HANNA GJ, Lau CJ, Mahmood U, Supplee JG, et al
    Salivary HPV DNA informs locoregional disease status in advanced HPV-associated oropharyngeal cancer.
    Oral Oncol. 2019;95:120-126.
    PubMed     Abstract available


    July 2019
  372. JAYARAJ R, Kumarasamy C, Madhav MR, Shetty S, et al
    Clinical validation of the Salivary HPV DNA assessment and its link to the locoregional disease burden in advanced HPV associated oropharyngeal cancer.
    Oral Oncol. 2019 Jul 30. pii: S1368-8375(19)30264.
    PubMed    


  373. SHI L, Wang Y, Li C, Liu W, et al
    Current evidence on DNA aneuploidy cytology in noninvasive detection of oral cancer.
    Oral Oncol. 2019 Jul 9. pii: S1368-8375(19)30244.
    PubMed     Abstract available


  374. KOKKALI S, Ntokou A, Drizou M, Perdikari K, et al
    Nivolumab in patients with rare head and neck carcinomas: A single center's experience.
    Oral Oncol. 2019 Jul 9. pii: S1368-8375(19)30237.
    PubMed     Abstract available


  375. SUROV A, Meyer HJ, Hohn AK, Wienke A, et al
    Combined parameter SUVmax/ADCmean predicts microvessel density in head and neck squamous cell carcinoma. Preliminary results.
    Oral Oncol. 2019 Jul 3. pii: S1368-8375(19)30227.
    PubMed    


  376. ECONOMOPOULOU P, Koutsodontis G, Strati A, Kirodimos E, et al
    Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC).
    Oral Oncol. 2019;94:93-100.
    PubMed     Abstract available


  377. CHEN X, Liang W, Wan N, Zhang L, et al
    Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2019;94:80-85.
    PubMed     Abstract available


  378. SUN XS, Liang YJ, Liu SL, Li XY, et al
    Establishment and validation of a nomogram for predicting survival in patients with de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2019;94:73-79.
    PubMed     Abstract available


  379. DEN TOOM IJ, Boeve K, van Weert S, Bloemena E, et al
    High rate of unexpected lymphatic drainage patterns and a high accuracy of the sentinel lymph node biopsy in oral cancer after previous neck treatment.
    Oral Oncol. 2019;94:68-72.
    PubMed     Abstract available


  380. DI CREDICO G, Edefonti V, Polesel J, Pauli F, et al
    Joint effects of intensity and duration of cigarette smoking on the risk of head and neck cancer: A bivariate spline model approach.
    Oral Oncol. 2019;94:47-57.
    PubMed     Abstract available


  381. BENCHETRIT L, Torabi SJ, Tate JP, Mehra S, et al
    Gender disparities in head and neck cancer chemotherapy clinical trials participation and treatment.
    Oral Oncol. 2019;94:32-40.
    PubMed     Abstract available


  382. CHOI WR, Roh JL, Gong G, Cho KJ, et al
    Multifocality of papillary thyroid carcinoma as a risk factor for disease recurrence.
    Oral Oncol. 2019;94:106-110.
    PubMed     Abstract available


  383. ROHDE M, Nielsen AL, Johansen J, Sorensen JA, et al
    Upfront PET/CT affects management decisions in patients with recurrent head and neck squamous cell carcinoma.
    Oral Oncol. 2019;94:1-7.
    PubMed     Abstract available


    June 2019
  384. CHARGI N, Ansari E, Huiskamp LFJ, Bol G, et al
    Agreement between skeletal muscle mass measurements using computed tomography imaging and magnetic resonance imaging in head and neck cancer patients.
    Oral Oncol. 2019 Jun 25. pii: S1368-8375(19)30211.
    PubMed    


  385. IQBAL MS, Kovarik J, Kelly C
    Limiting radiotherapy field to ipsilateral side only in unresected lateralised HPV positive N2b squamous cell carcinoma of the tonsil.
    Oral Oncol. 2019 Jun 12. pii: S1368-8375(19)30203.
    PubMed    


  386. CHEN JJ, Harris JP, Kong CS, Sunwoo JB, et al
    Corrigendum to 'Clinical perineural invasion of cutaneous head and neck cancer: Impact of radiotherapy, imaging, and nerve growth factor receptors on symptom control and prognosis'. [Oral Oncol. 85 (2018) 60-67].
    Oral Oncol. 2019 Jun 4. pii: S1368-8375(19)30171.
    PubMed    


  387. MCMULLEN CP, Garneau J, Weimar E, Ali S, et al
    Occult contralateral nodal disease in oropharyngeal squamous cell carcinoma patients undergoing primary TORS with bilateral neck dissection.
    Oral Oncol. 2019;93:96-100.
    PubMed     Abstract available


  388. CAO C, Yang P, Xu Y, Niu T, et al
    Feasibility of multiparametric imaging with PET/MR in nasopharyngeal carcinoma: A pilot study.
    Oral Oncol. 2019;93:91-95.
    PubMed     Abstract available


  389. TROIANO G, Caponio VCA, Adipietro I, Tepedino M, et al
    Prognostic significance of CD68(+) and CD163(+) tumor associated macrophages in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2019;93:66-75.
    PubMed     Abstract available


  390. RAMBEAU A, Bastit V, Thureau S, Thariat J, et al
    Impact of locoregional irradiation in patients with upfront metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2019;93:46-51.
    PubMed     Abstract available


  391. LIAO W, Huang J, Wu Q, Zhu G, et al
    Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis.
    Oral Oncol. 2019;93:15-20.
    PubMed     Abstract available


  392. FUJII T, Miyabe J, Yoshii T, Suzuki M, et al
    Metabolic tumor volume of metastatic lymph nodes and survival after total laryngectomy in laryngeal and hypopharyngeal cancer.
    Oral Oncol. 2019;93:107-113.
    PubMed     Abstract available


  393. CHEN X, Zheng Y, Tatsuoka C, Muzic RF Jr, et al
    Chemoradiotherapy-related carotid artery inflammation in head and neck cancer patients quantified by [(18)F]FDG PET/CT.
    Oral Oncol. 2019;93:101-106.
    PubMed     Abstract available


  394. BONOMO P, Greto D, Desideri I, Loi M, et al
    Clinical outcome of stereotactic body radiotherapy for lung-only oligometastatic head and neck squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?
    Oral Oncol. 2019;93:1-7.
    PubMed     Abstract available


    May 2019
  395. BOSSI P, Seront E, Machiels JP
    May we rely on induction chemotherapy again as a biological selection of radiosensitive head and neck cancer?
    Oral Oncol. 2019 May 21. pii: S1368-8375(19)30158.
    PubMed    


  396. FERNANDEZ-FEIJOO J, Fernandez-Varela M, Diniz-Freitas M, Diz-Dios P, et al
    Why refer possible oral cancer to the dentist for assessment?
    Oral Oncol. 2019 May 14. pii: S1368-8375(19)30153.
    PubMed    


  397. ABRAM TJ, Floriano PN, James R, Kerr AR, et al
    Development of a cytology-based multivariate analytical risk index for oral cancer.
    Oral Oncol. 2019;92:6-11.
    PubMed     Abstract available


  398. LIANG YJ, Sun XS, Yang ZC, Tang QN, et al
    Effect of local treatment for metastasis and its sequence with chemotherapy on prognosis of post-treatment metastatic nasopharyngeal carcinoma patients.
    Oral Oncol. 2019;92:40-45.
    PubMed     Abstract available


  399. GREENE S, Patel P, Allen CT
    How patients with an intact immune system develop head and neck cancer.
    Oral Oncol. 2019;92:26-32.
    PubMed     Abstract available


  400. SUNNY SP, Agarwal S, James BL, Heidari E, et al
    Intra-operative point-of-procedure delineation of oral cancer margins using optical coherence tomography.
    Oral Oncol. 2019;92:12-19.
    PubMed     Abstract available


  401. SMITH WH, Luskin I, Resende Salgado L, Scarborough BM, et al
    Risk of prolonged opioid use among cancer patients undergoing curative intent radiation therapy for head and neck malignancies.
    Oral Oncol. 2019;92:1-5.
    PubMed     Abstract available


  402. MARTIN-GOMEZ L, Fulp WJ, Schell MJ, Sirak B, et al
    Oral gargle-tumor biopsy human papillomavirus (HPV) agreement and associated factors among oropharyngeal squamous cell carcinoma (OPSCC) cases.
    Oral Oncol. 2019;92:85-91.
    PubMed     Abstract available


  403. BURR AR, Harari PM, Ko HC, Bruce JY, et al
    Reducing radiotherapy target volume expansion for patients with HPV-associated oropharyngeal cancer.
    Oral Oncol. 2019;92:52-56.
    PubMed     Abstract available


    April 2019
  404. HARTMAN DJ, Ahmad FS, Ferris RL, Rimm DL, et al
    Corrigendum to "Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma" [Oral Oncol. 86 (2018) 278-287].
    Oral Oncol. 2019 Apr 30. pii: S1368-8375(19)30128.
    PubMed    


  405. DE FELICE F, Polimeni A, Tombolini V
    Human papillomavirus (HPV) vaccine and HPV-related head and neck cancer: What's next?
    Oral Oncol. 2019 Apr 4. pii: S1368-8375(19)30101.
    PubMed    


  406. CHAN JYW, Wong STS, Wei WI
    Surgical salvage of recurrent T3 nasopharyngeal carcinoma: Prognostic significance of clivus, maxillary, temporal and sphenoid bone invasion.
    Oral Oncol. 2019;91:85-91.
    PubMed     Abstract available


  407. LUO WJ, Feng YF, Guo R, Tang LL, et al
    Patterns of EBV-positive cervical lymph node involvement in head and neck cancer and implications for the management of nasopharyngeal carcinoma T0 classification.
    Oral Oncol. 2019;91:7-12.
    PubMed     Abstract available


  408. EZE N, Lee JW, Yang DH, Zhu F, et al
    PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2019;91:69-78.
    PubMed     Abstract available


  409. TSAI MS, Chen WC, Lu CH, Chen MF, et al
    The prognosis of head and neck squamous cell carcinoma related to immunosuppressive tumor microenvironment regulated by IL-6 signaling.
    Oral Oncol. 2019;91:47-55.
    PubMed     Abstract available


  410. GUY JB, Benna M, Xia Y, Daguenet E, et al
    Quality insurance in head and neck cancer multidisciplinary team meetings: A watchful eye on real-life experience.
    Oral Oncol. 2019;91:35-38.
    PubMed     Abstract available


  411. SONG E, Ahn J, Oh HS, Jeon MJ, et al
    Time trends of thyroglobulin antibody in ablated papillary thyroid carcinoma patients: Can we predict the rate of negative conversion?
    Oral Oncol. 2019;91:29-34.
    PubMed     Abstract available


  412. GUO Q, Lu T, Hui Huang S, O'Sullivan B, et al
    Depicting distant metastatic risk by refined subgroups derived from the 8th edition nasopharyngeal carcinoma TNM.
    Oral Oncol. 2019;91:113-120.
    PubMed     Abstract available


    March 2019
  413. JAYARAJ R, Kumarasamy C, Royam MM, Sabarimurugan S, et al
    Prognostic implications of pathologic lymph nodes in HPV-positive oropharyngeal cancers: Clinical validity and strategies for routine clinical practice.
    Oral Oncol. 2019 Mar 8. pii: S1368-8375(19)30074.
    PubMed    


  414. DE BREE R, Takes RP, Shah JP, Hamoir M, et al
    Elective neck dissection in oral squamous cell carcinoma: Past, present and future.
    Oral Oncol. 2019;90:87-93.
    PubMed     Abstract available


  415. EL-SALEM F, Mansour M, Gitman M, Miles BA, et al
    Real-time PCR HPV genotyping in fine needle aspirations of metastatic head and neck squamous cell carcinoma: Exposing the limitations of conventional p16 immunostaining.
    Oral Oncol. 2019;90:74-79.
    PubMed     Abstract available


  416. GHANIZADA M, Jakobsen KK, Gronhoj C, von Buchwald C, et al
    The effects of checkpoint inhibition on head and neck squamous cell carcinoma: A systematic review.
    Oral Oncol. 2019;90:67-73.
    PubMed     Abstract available


  417. KANG S
    Organ preservation in laryngeal and hypopharyngeal cancer.
    Oral Oncol. 2019;90:6-7.
    PubMed    


  418. GUPTA A, Stokes W, Eguchi M, Hararah M, et al
    Statin use associated with improved overall and cancer specific survival in patients with head and neck cancer.
    Oral Oncol. 2019;90:54-66.
    PubMed     Abstract available


  419. YUNG CS, Leung DKC, Cheung JPY
    The prevalence and impact of cervical spine pathologies in patients with nasopharyngeal carcinoma.
    Oral Oncol. 2019;90:48-53.
    PubMed     Abstract available


  420. FRIEDMAN J, Padget M, Lee J, Schlom J, et al
    Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells.
    Oral Oncol. 2019;90:38-44.
    PubMed     Abstract available


  421. WANG YQ, Lv JW, Tang LL, Du XJ, et al
    Effect of prior cancer on trial eligibility and treatment outcomes in nasopharyngeal carcinoma: Implications for clinical trial accrual.
    Oral Oncol. 2019;90:23-29.
    PubMed     Abstract available


  422. LIU J, Zhang Z, Huang H, Xu S, et al
    Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: A single-institution matched-pair analysis.
    Oral Oncol. 2019;90:17-22.
    PubMed     Abstract available


  423. GARCIA GCTE, Gorphe P, Hartl D, Ammari S, et al
    Computed tomography evaluation after induction chemotherapy for T3 laryngeal cancer: Does response correlate with vocal cord mobility?
    Oral Oncol. 2019;90:13-16.
    PubMed     Abstract available


  424. BADR H, Sobrero M, Chen J, Kotz T, et al
    Associations between pre-, post-, and peri-operative variables and health resource use following surgery for head and neck cancer.
    Oral Oncol. 2019;90:102-108.
    PubMed     Abstract available


  425. MIAO J, Wang L, Zhu M, Xiao W, et al
    Corrigendum to "Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy" [Oral Oncol. 89 (2019)
    Oral Oncol. 2019;90:136.
    PubMed    


  426. MIAO J, Wang L, Zhu M, Xiao W, et al
    Reprint of Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy.
    Oral Oncol. 2019;90:126-133.
    PubMed     Abstract available


    February 2019
  427. SALEH K, Saada E, Auger N, Mayache-Badis L, et al
    Successful treatment with trastuzumab in HER2-positive squamous cell carcinoma of the head and neck.
    Oral Oncol. 2019 Feb 14. pii: S1368-8375(19)30044.
    PubMed    


  428. YU ST, Xiao ZZ
    Letter to the Editor regarding, "Total thyroidectomy versus lobectomy for intermediate-risk papillary thyroid carcinoma: A single-institution matched-pair analysis".
    Oral Oncol. 2019 Feb 14. pii: S1368-8375(19)30045.
    PubMed    


  429. GAUBATZ ME, Bukatko AR, Simpson MC, Polednik KM, et al
    Racial and socioeconomic disparities associated with 90-day mortality among patients with head and neck cancer in the United States.
    Oral Oncol. 2019;89:95-101.
    PubMed     Abstract available


  430. CHUNG EJ, Jeong WJ, Jung YH, Kwon SK, et al
    Long-term oncological and functional outcomes of induction chemotherapy followed by (chemo)radiotherapy vs definitive chemoradiotherapy vs surgery-based therapy in locally advanced stage III/IV hypopharyngeal cancer: Multicenter review of 266 cases.
    Oral Oncol. 2019;89:84-94.
    PubMed     Abstract available


  431. NAM KIM Y, Kim M, Seon Ahn H, Kim K, et al
    Refining the tumor-node-metastasis staging system for individualized treatment of differentiated thyroid carcinoma.
    Oral Oncol. 2019;89:8-13.
    PubMed     Abstract available


  432. TEFT WA, Winquist E, Nichols AC, Kuruvilla S, et al
    Predictors of cisplatin-induced ototoxicity and survival in chemoradiation treated head and neck cancer patients.
    Oral Oncol. 2019;89:72-78.
    PubMed     Abstract available


  433. HUANG CC, Lin CN, Chung CH, Hwang JS, et al
    Cost-effectiveness analysis of the oral cancer screening program in Taiwan.
    Oral Oncol. 2019;89:59-65.
    PubMed     Abstract available


  434. JACOBS CD, Barbour AB, Mowery YM
    The relative distribution of oral cancer in the United States by subsite.
    Oral Oncol. 2019;89:56-58.
    PubMed    


  435. SIMPSON MC, Challapalli SD, Cass LM, Zahirsha ZS, et al
    Impact of gender on the association between marital status and head and neck cancer outcomes.
    Oral Oncol. 2019;89:48-55.
    PubMed     Abstract available


  436. MIAO J, Wang L, Zhu M, Xiao W, et al
    Long-term survival and late toxicities of elderly nasopharyngeal carcinoma (NPC) patients treated by high-total- and fractionated-dose simultaneous modulated accelerated radiotherapy with or without chemotherapy.
    Oral Oncol. 2019;89:40-47.
    PubMed    


  437. CHIKAMATSU K, Tada H, Takahashi H, Kuwabara-Yokobori Y, et al
    Expression of immune-regulatory molecules in circulating tumor cells derived from patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2019;89:34-39.
    PubMed     Abstract available


  438. HEALY CM, Moran GP
    The microbiome and oral cancer: More questions than answers.
    Oral Oncol. 2019;89:30-33.
    PubMed     Abstract available


  439. FARQUHAR DR, Masood MM, Lenze NR, McDaniel P, et al
    Travel time to provider is associated with advanced stage at diagnosis among low income head and neck squamous cell carcinoma patients in North Carolina.
    Oral Oncol. 2019;89:115-120.
    PubMed     Abstract available


  440. PENG L, Xu C, Chen YP, Guo R, et al
    Optimizing the cumulative cisplatin dose during radiotherapy in nasopharyngeal carcinoma: Dose-effect analysis for a large cohort.
    Oral Oncol. 2019;89:102-106.
    PubMed     Abstract available


  441. VARRA V, Ross RB, Juloori A, Campbell S, et al
    Selectively sparing the submandibular gland when level Ib lymph nodes are included in the radiation target volume: An initial safety analysis of a novel planning objective.
    Oral Oncol. 2019;89:79-83.
    PubMed     Abstract available


  442. ROSS RB, Juloori A, Varra V, Ward MC, et al
    Five-year outcomes of sparing level IB in node-positive, human papillomavirus-associated oropharyngeal carcinoma: A safety and efficacy analysis.
    Oral Oncol. 2019;89:66-71.
    PubMed     Abstract available


  443. EL ASMAR M, Tsai HL, Fakhry C, Maroun CA, et al
    The prognostic impact of pathologic lymph nodes in HPV-positive oropharyngeal cancers.
    Oral Oncol. 2019;89:23-29.
    PubMed     Abstract available


  444. MESHMAN J, Velez MA, Wang PC, Abemayor E, et al
    Immunologic mediators of outcome for irradiated oropharyngeal carcinoma based on human papillomavirus status.
    Oral Oncol. 2019;89:121-126.
    PubMed     Abstract available


  445. WU S, Liu J, Quan R, Han L, et al
    A rare case of nasopharyngeal adenoid cystic carcinoma treated with cetuximab-based induction therapy followed by concurrent chemoradiotherapy.
    Oral Oncol. 2019;89:161-163.
    PubMed    


    January 2019
  446. PAOLINI F, Bonomo C, Terrenato I, Pennetti A, et al
    Beta human papillomaviruses in middle ear squamous cell carcinoma.
    Oral Oncol. 2019 Jan 18. pii: S1368-8375(19)30004.
    PubMed    


  447. JAYARAJ R, Kumarasamy C
    Conceptual interpretation of analysing and reporting of results on systematic review and meta-analysis of optimal extent of lateral neck dissection for well-differentiated thyroid carcinoma with metastatic lateral neck lymph nodes.
    Oral Oncol. 2019 Jan 3. pii: S1368-8375(18)30497.
    PubMed    


  448. FOY JP, Bertolus C, Saintigny P
    Oral cancer prevention worldwide: Challenges and perspectives.
    Oral Oncol. 2019;88:91-94.
    PubMed    


  449. HAQUE S, Karivedu V, Riaz MK, Choi D, et al
    High-risk pathological features at the time of salvage surgery predict poor survival after definitive therapy in patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2019;88:9-15.
    PubMed     Abstract available


  450. MAY ME JR, Cash ED, Silverman CL, Redman RA, et al
    Prognostic factors and selection criteria in the retreatment of head and neck cancers.
    Oral Oncol. 2019;88:85-90.
    PubMed     Abstract available


  451. ALTAMURA G, Borzacchiello G
    HPV related head and neck squamous cell carcinoma: New evidences for an emerging spontaneous animal model.
    Oral Oncol. 2019;88:84.
    PubMed    


  452. MARTENS RM, Noij DP, Ali M, Koopman T, et al
    Functional imaging early during (chemo)radiotherapy for response prediction in head and neck squamous cell carcinoma; a systematic review.
    Oral Oncol. 2019;88:75-83.
    PubMed     Abstract available


  453. MORENO AC, Frank SJ, Garden AS, Rosenthal DI, et al
    Intensity modulated proton therapy (IMPT) - The future of IMRT for head and neck cancer.
    Oral Oncol. 2019;88:66-74.
    PubMed     Abstract available


  454. GREGOIRE V, Ng WT
    Special section on intensity-modulated radiation therapy for head and neck cancer (IMRT).
    Oral Oncol. 2019;88:49-50.
    PubMed    


  455. GOEL AN, Frangos MI, Raghavan G, Lazaro SL, et al
    The impact of treatment package time on survival in surgically managed head and neck cancer in the United States.
    Oral Oncol. 2019;88:39-48.
    PubMed     Abstract available


  456. EVRARD D, Szturz P, Tijeras-Raballand A, Astorgues-Xerri L, et al
    Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.
    Oral Oncol. 2019;88:29-38.
    PubMed     Abstract available


  457. SHETTY SS, Vishal Rao US
    8 "S" in oral cancer.
    Oral Oncol. 2019;88:27-28.
    PubMed    


  458. KARSTEN RT, Stuiver MM, van der Molen L, Navran A, et al
    From reactive to proactive tube feeding during chemoradiotherapy for head and neck cancer: A clinical prediction model-based approach.
    Oral Oncol. 2019;88:172-179.
    PubMed     Abstract available


  459. LIU JC, Bhayani M, Kuchta K, Galloway T, et al
    Patterns of distant metastasis in head and neck cancer at presentation: Implications for initial evaluation.
    Oral Oncol. 2019;88:131-136.
    PubMed     Abstract available


  460. KIM Y, Roh JL, Kim JS, Lee JH, et al
    Chest radiography or chest CT plus head and neck CT versus (18)F-FDG PET/CT for detection of distant metastasis and synchronous cancer in patients with head and neck cancer.
    Oral Oncol. 2019;88:109-114.
    PubMed     Abstract available


  461. FENG RM, Chang ET, Liu Z, Liu Q, et al
    Reproductive history and risk of nasopharyngeal carcinoma: A population-based case-control study in southern China.
    Oral Oncol. 2019;88:102-108.
    PubMed     Abstract available


  462. SILVERMAN DA, Puram SV, Rocco JW, Old MO, et al
    Salvage laryngectomy following organ-preservation therapy - An evidence-based review.
    Oral Oncol. 2019;88:137-144.
    PubMed     Abstract available


  463. LIU HY, Milne R, Lock G, Panizza BJ, et al
    Utility of a repeat PET/CT scan in HPV-associated Oropharyngeal Cancer following incomplete nodal response from (chemo)radiotherapy.
    Oral Oncol. 2019;88:153-159.
    PubMed     Abstract available


    December 2018
  464. JAYARAJ R, Kumarasamy C
    Letter to the Editor about the Article: "Performance of different imaging techniques in the diagnosis of head and neck cancer mandibular invasion: A systematic review and meta-analysis".
    Oral Oncol. 2018 Dec 31. pii: S1368-8375(18)30490.
    PubMed    


  465. JAYARAJ R, Kumarasamy C, Samiappan S, Swaminathan P, et al
    Letter to the Editor regarding, "The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis".
    Oral Oncol. 2018 Dec 19. pii: S1368-8375(18)30482.
    PubMed    


  466. JAYARAJ R, Kumarasamy C
    Comment on, "Survival for HPV-positive oropharyngeal squamous cell carcinoma with surgical versus non-surgical treatment approach: A systematic review and meta-analysis".
    Oral Oncol. 2018 Dec 19. pii: S1368-8375(18)30483.
    PubMed    


  467. DENG L, Cao Y, Lin J
    Regional recurrence rate of lymph-node-positive thyroid carcinoma after selective or comprehensive neck dissection.
    Oral Oncol. 2018 Dec 13. pii: S1368-8375(18)30456.
    PubMed    


  468. KIM M, Kim HI, Jeon MJ, Kim HK, et al
    Eighth edition of tumor-node-metastasis staging system improve survival predictability for papillary, but not follicular thyroid carcinoma: A multicenter cohort study.
    Oral Oncol. 2018;87:97-103.
    PubMed     Abstract available


  469. BAIRD BJ, Sung CK, Beadle BM, Divi V, et al
    Treatment of early-stage laryngeal cancer: A comparison of treatment options.
    Oral Oncol. 2018;87:8-16.
    PubMed     Abstract available


  470. MCCLELLAND S 3RD, Andrews JZ, Chaudhry H, Teckie S, et al
    Prophylactic versus reactive gastrostomy tube placement in advanced head and neck cancer treated with definitive chemoradiotherapy: A systematic review.
    Oral Oncol. 2018;87:77-81.
    PubMed     Abstract available


  471. D'CRUZ AK, Vaish R, Dhar H
    Oral cancers: Current status.
    Oral Oncol. 2018;87:64-69.
    PubMed     Abstract available


  472. CHUANG SL, Wang CP, Chen MK, Su WW, et al
    Malignant transformation to oral cancer by subtype of oral potentially malignant disorder: A prospective cohort study of Taiwanese nationwide oral cancer screening program.
    Oral Oncol. 2018;87:58-63.
    PubMed     Abstract available


  473. TANAKA N, Osman AA, Takahashi Y, Lindemann A, et al
    Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
    Oral Oncol. 2018;87:49-57.
    PubMed     Abstract available


  474. DUA B, Chufal KS, Bhatnagar A, Thakwani A, et al
    Nodal volume as a prognostic factor in locally advanced head and neck cancer: Identifying candidates for elective neck dissection after chemoradiation with IGRT from a single institutional prospective series from the Indian subcontinent.
    Oral Oncol. 2018;87:179-185.
    PubMed     Abstract available


  475. OLATUNJI I
    Potential application of tumor suppressor microRNAs for targeted therapy in head and neck cancer: A mini-review.
    Oral Oncol. 2018;87:165-169.
    PubMed     Abstract available


  476. NAM SH, Bae MR, Roh JL, Gong G, et al
    A comparison of the 7th and 8th editions of the AJCC staging system in terms of predicting recurrence and survival in patients with papillary thyroid carcinoma.
    Oral Oncol. 2018;87:158-164.
    PubMed     Abstract available


  477. RANGEL JB, Thuler LCS, Pinto JFDC
    Prevalence of hepatitis C virus infection and its impact on the prognosis of head and neck cancer patients.
    Oral Oncol. 2018;87:138-143.
    PubMed     Abstract available


  478. WON HR, Chang JW, Kang YE, Kang JY, et al
    Optimal extent of lateral neck dissection for well-differentiated thyroid carcinoma with metastatic lateral neck lymph nodes: A systematic review and meta-analysis.
    Oral Oncol. 2018;87:117-125.
    PubMed     Abstract available


  479. KEARNEY V, Chan JW, Valdes G, Solberg TD, et al
    The application of artificial intelligence in the IMRT planning process for head and neck cancer.
    Oral Oncol. 2018;87:111-116.
    PubMed     Abstract available


  480. HIRSCHMANN A, Lupatsch JE, Schwenkglenks M, Panje CM, et al
    Cost-effectiveness of nivolumab in the treatment of head and neck cancer.
    Oral Oncol. 2018;87:104-110.
    PubMed     Abstract available


    November 2018
  481. HUANG NS, Wei WJ, Qu N, Wang YL, et al
    Lingual ectopic papillary thyroid carcinoma: Two case reports and review of the literature.
    Oral Oncol. 2018 Nov 22. pii: S1368-8375(18)30428.
    PubMed     Abstract available


  482. LIU W, Chen S, Yang W
    The diverse cutoff of PD-L1 positivity and negativity in studies regarding head and neck squamous cell carcinoma.
    Oral Oncol. 2018 Nov 2. pii: S1368-8375(18)30404.
    PubMed    


  483. ANDREASSEN CN, Eriksen JG, Jensen K, Hansen CR, et al
    IMRT - Biomarkers for dose escalation, dose de-escalation and personalized medicine in radiotherapy for head and neck cancer.
    Oral Oncol. 2018;86:91-99.
    PubMed     Abstract available


  484. YANG WF, Wong MCM, Thomson PJ, Li KY, et al
    The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2018;86:81-90.
    PubMed     Abstract available


  485. KIM M, Kim HK, Kim HI, Kim EH, et al
    Modification of the eight-edition tumor-node-metastasis staging system with N1b for papillary thyroid carcinoma: A multi-institutional cohort study.
    Oral Oncol. 2018;86:48-52.
    PubMed     Abstract available


  486. BONOMI MR, Blakaj A, Blakaj D
    Organ preservation for advanced larynx cancer: A review of chemotherapy and radiation combination strategies.
    Oral Oncol. 2018;86:301-306.
    PubMed     Abstract available


  487. EVANS M, Beasley M
    Target delineation for postoperative treatment of head and neck cancer.
    Oral Oncol. 2018;86:288-295.
    PubMed     Abstract available


  488. HARTMAN DJ, Ahmad F, Ferris RL, Rimm DL, et al
    Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma.
    Oral Oncol. 2018;86:278-287.
    PubMed     Abstract available


  489. PENG L, Chen YP, Xu C, Tang LL, et al
    A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma.
    Oral Oncol. 2018;86:258-265.
    PubMed     Abstract available


  490. FUJIWARA T, Eguchi T, Sogawa C, Ono K, et al
    Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab.
    Oral Oncol. 2018;86:251-257.
    PubMed     Abstract available


  491. SEGRELLES C, Paramio JM, Lorz C
    The transcriptional co-activator YAP: A new player in head and neck cancer.
    Oral Oncol. 2018;86:25-32.
    PubMed     Abstract available


  492. GARNEAU JC, Bakst RL, Miles BA
    Hypopharyngeal cancer: A state of the art review.
    Oral Oncol. 2018;86:244-250.
    PubMed     Abstract available


  493. KASHYAP T, Pramanik KK, Nath N, Mishra P, et al
    Crosstalk between Raf-MEK-ERK and PI3K-Akt-GSK3beta signaling networks promotes chemoresistance, invasion/migration and stemness via expression of CD44 variants (v4 and v6) in oral cancer.
    Oral Oncol. 2018;86:234-243.
    PubMed     Abstract available


  494. GUJRAL DM, Nutting CM
    Patterns of failure, treatment outcomes and late toxicities of head and neck cancer in the current era of IMRT.
    Oral Oncol. 2018;86:225-233.
    PubMed     Abstract available


  495. SPECTOR ME, Rosko AJ, Swiecicki PL, Chad Brenner J, et al
    From VA Larynx to the future of chemoselection: Defining the role of induction chemotherapy in larynx cancer.
    Oral Oncol. 2018;86:200-205.
    PubMed     Abstract available


  496. ESKANDER A, Blakaj DM, Dziegielewski PT
    Decision making in advanced larynx cancer: An evidenced based review.
    Oral Oncol. 2018;86:195-199.
    PubMed     Abstract available


  497. GENSHEIMER MF, Le QT
    Adaptive radiotherapy for head and neck cancer: Are we ready to put it into routine clinical practice?
    Oral Oncol. 2018;86:19-24.
    PubMed     Abstract available


  498. QIAO X, Liu W, Cao Y, Miao C, et al
    Performance of different imaging techniques in the diagnosis of head and neck cancer mandibular invasion: A systematic review and meta-analysis.
    Oral Oncol. 2018;86:150-164.
    PubMed     Abstract available


  499. CHUANG HC, Chou MH, Chien CY, Chuang JH, et al
    Triggering TLR3 pathway promotes tumor growth and cisplatin resistance in head and neck cancer cells.
    Oral Oncol. 2018;86:141-149.
    PubMed     Abstract available


  500. ZANDBERG DP, Cullen K, Bentzen SM, Goloubeva OG, et al
    Definitive radiation with concurrent cetuximab vs. radiation with or without concurrent cytotoxic chemotherapy in older patients with squamous cell carcinoma of the head and neck: Analysis of the SEER-medicare linked database.
    Oral Oncol. 2018;86:132-140.
    PubMed     Abstract available


  501. SHAIKH MH, Idris A, Johnson NW, Fallaha S, et al
    Aurora kinases are a novel therapeutic target for HPV-positive head and neck cancers.
    Oral Oncol. 2018;86:105-112.
    PubMed     Abstract available


  502. DO JH, Yoon IJ, Cho YK, Ahn JS, et al
    Comparison of hospital based and home based exercise on quality of life, and neck and shoulder function in patients with spinal accessary nerve injury after head and neck cancer surgery.
    Oral Oncol. 2018;86:100-104.
    PubMed     Abstract available


  503. PIKE LRG, Hwang WL, Royce TJ, Sanford NN, et al
    HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx.
    Oral Oncol. 2018;86:69-74.
    PubMed     Abstract available


  504. SATHASIVAM HP, Bhatia R, Bradley P, Robson A, et al
    Concurrent HPV-related oropharyngeal carcinoma in four couples.
    Oral Oncol. 2018;86:33-37.
    PubMed     Abstract available


  505. CANNON RB, Houlton JJ, Patel S, Raju S, et al
    Patterns of cervical node positivity, regional failure rates, and fistula rates for HPV+ oropharyngeal squamous cell carcinoma treated with transoral robotic surgery (TORS).
    Oral Oncol. 2018;86:296-300.
    PubMed     Abstract available


  506. HUANG SH, Hahn E, Tsang RK, Chen ZJ, et al
    The interplay of IMRT and transoral surgery in HPV-mediated oropharyngeal cancer: Getting the balance right.
    Oral Oncol. 2018;86:171-180.
    PubMed     Abstract available


  507. SINHA P, Karadaghy OA, Doering MM, Tuuli MG, et al
    Survival for HPV-positive oropharyngeal squamous cell carcinoma with surgical versus non-surgical treatment approach: A systematic review and meta-analysis.
    Oral Oncol. 2018;86:121-131.
    PubMed     Abstract available


    October 2018
  508. CAPPELLI E, Degan P, Dufour C, Ravera S, et al
    Aerobic metabolism dysfunction as one of the links between Fanconi anemia-deficient pathway and the aggressive cell invasion in head and neck cancer cells.
    Oral Oncol. 2018 Oct 20. pii: S1368-8375(18)30370.
    PubMed    


  509. SHETTY SS, Vishal Rao US
    Changing sexual practices: A possible link to oral cancer.
    Oral Oncol. 2018 Oct 10. pii: S1368-8375(18)30356.
    PubMed    


  510. LI PJ, Mo HY, Luo DH, Hu WH, et al
    The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Oral Oncol. 2018;85:95-100.
    PubMed     Abstract available


  511. AMBATIPUDI S, Langdon R, Richmond RC, Suderman M, et al
    DNA methylation derived systemic inflammation indices are associated with head and neck cancer development and survival.
    Oral Oncol. 2018;85:87-94.
    PubMed     Abstract available


  512. LU L, Sheng Y, Zhang G, Li Y, et al
    Temporal lobe injury patterns following intensity modulated radiotherapy in a large cohort of nasopharyngeal carcinoma patients.
    Oral Oncol. 2018;85:8-14.
    PubMed     Abstract available


  513. SAKA HERRAN C, Jane-Salas E, Estrugo Devesa A, Lopez-Lopez J, et al
    Protective effects of metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic review.
    Oral Oncol. 2018;85:68-81.
    PubMed     Abstract available


  514. CHEN JJ, Harris JP, Kong CS, Sunwoo JB, et al
    Clinical perineural invasion of cutaneous head and neck cancer: Impact of radiotherapy, imaging, and nerve growth factor receptors on symptom control and prognosis.
    Oral Oncol. 2018;85:60-67.
    PubMed     Abstract available


  515. LEE DJ, Eun YG, Rho YS, Kim EH, et al
    Three distinct genomic subtypes of head and neck squamous cell carcinoma associated with clinical outcomes.
    Oral Oncol. 2018;85:44-51.
    PubMed     Abstract available


  516. LIN DJ, McConkey CC, Nankivell P, Dunn J, et al
    The impact of institutional clinical trial recruitment versus hospital volume on survival outcomes of patients with head and neck cancer: An analysis of the PET-NECK trial outcomes, UKCRN portfolio, and Hospital Episode Statistics (HES) in England.
    Oral Oncol. 2018;85:40-43.
    PubMed     Abstract available


  517. SRIDHARAN V, Rahman RM, Huang RY, Chau NG, et al
    Radiologic predictors of immune checkpoint inhibitor response in advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2018;85:29-34.
    PubMed     Abstract available


    September 2018
  518. MORAND GB, Helmchen BM, Steinert HC, Schmid C, et al
    18F-Choline-PET in parathyroid carcinoma.
    Oral Oncol. 2018 Sep 28. pii: S1368-8375(18)30324.
    PubMed    


  519. PANTA P
    'Meditation Training Intervention' - A necessary shift for head and neck cancer patients.
    Oral Oncol. 2018 Sep 8. pii: S1368-8375(18)30316.
    PubMed    


  520. SALOURA V, Vougiouklakis T, Burkitt K, Nakamura Y, et al
    Corrigendum to "The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck" [Oral Oncol. 81 (2018) 100-108].
    Oral Oncol. 2018 Sep 7. pii: S1368-8375(18)30313.
    PubMed    


  521. DRONKERS EAC, Hoesseini A, de Boer MF, Offerman MPJ, et al
    Communication of prognosis in head and neck cancer patients; a descriptive qualitative analysis.
    Oral Oncol. 2018;84:76-81.
    PubMed     Abstract available


  522. CHEN MM, Colevas AD, Megwalu U, Divi V, et al
    Survival benefit of post-operative chemotherapy for intermediate-risk advanced stage head and neck cancer differs with patient age.
    Oral Oncol. 2018;84:71-75.
    PubMed     Abstract available


  523. FARQUHAR DR, Tanner AM, Masood MM, Patel SR, et al
    Oral tongue carcinoma among young patients: An analysis of risk factors and survival.
    Oral Oncol. 2018;84:7-11.
    PubMed     Abstract available


  524. WEISS J, Gilbert J, Deal AM, Weissler M, et al
    Induction chemotherapy with carboplatin, nab-paclitaxel and cetuximab for at least N2b nodal status or surgically unresectable squamous cell carcinoma of the head and neck.
    Oral Oncol. 2018;84:46-51.
    PubMed     Abstract available


  525. PARK SY, Kim HI, Choi JY, Choe JH, et al
    Low versus high activity radioiodine remnant ablation for differentiated thyroid carcinoma with gross extrathyroidal extension invading only strap muscles.
    Oral Oncol. 2018;84:41-45.
    PubMed     Abstract available


  526. PENG LC, Hui X, Cheng Z, Bowers MR, et al
    Prospective evaluation of patient reported swallow function with the Functional Assessment of Cancer Therapy (FACT), MD Anderson Dysphagia Inventory (MDADI) and the Sydney Swallow Questionnaire (SSQ) in head and neck cancer patients.
    Oral Oncol. 2018;84:25-30.
    PubMed     Abstract available


  527. STOKES WA, Eguchi M, Amini A, Hararah MK, et al
    Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset.
    Oral Oncol. 2018;84:12-19.
    PubMed     Abstract available


  528. LALA M, Chirovsky D, Cheng JD, Mayawala K, et al
    Clinical outcomes with therapies for previously treated recurrent/metastatic head-and-neck squamous cell carcinoma (R/M HNSCC): A systematic literature review.
    Oral Oncol. 2018;84:108-120.
    PubMed     Abstract available


  529. LI Y, Xu T, Qian W, Lu X, et al
    Radiation-induced nasopharyngeal ulcers after intensity modulated radiotherapy in primary nasopharyngeal carcinoma patients: A dose-volume-outcome analysis.
    Oral Oncol. 2018;84:1-6.
    PubMed     Abstract available


  530. GELTZEILER M, Bertolet M, Albergotti W, Gleysteen J, et al
    Staging HPV-related oropharyngeal cancer: Validation of AJCC-8 in a surgical cohort.
    Oral Oncol. 2018;84:82-87.
    PubMed     Abstract available


    August 2018
  531. ANGELIDAKIS G, Sturgis EM, Economides MP, Jiang Y, et al
    Chronic hepatitis C virus infection on patients with nonoropharyngeal head and neck cancers.
    Oral Oncol. 2018 Aug 25. pii: S1368-8375(18)30303.
    PubMed    


  532. PATTERSON JM, McColl E, Carding PN, Wilson JA, et al
    Swallowing beyond six years post (chemo)radiotherapy for head and neck cancer; a cohort study.
    Oral Oncol. 2018;83:53-58.
    PubMed     Abstract available


  533. CHOI N, Park SI, Kim H, Sohn I, et al
    The impact of unplanned reoperations in head and neck cancer surgery on survival.
    Oral Oncol. 2018;83:38-45.
    PubMed     Abstract available


  534. LECHNER M, Chakravarthy AR, Walter V, Masterson L, et al
    Frequent HPV-independent p16/INK4A overexpression in head and neck cancer.
    Oral Oncol. 2018;83:32-37.
    PubMed     Abstract available


  535. MELISSANT HC, Jansen F, Schutte LER, Lissenberg-Witte BI, et al
    The course of sexual interest and enjoyment in head and neck cancer patients treated with primary (chemo)radiotherapy.
    Oral Oncol. 2018;83:120-126.
    PubMed     Abstract available


  536. HICKS DF, Bakst R, Doucette J, Kann BH, et al
    Impact of obesity on outcomes for patients with head and neck cancer.
    Oral Oncol. 2018;83:11-17.
    PubMed     Abstract available


  537. ESKANDER A, Krzyzanowska MK, Fischer HD, Liu N, et al
    Emergency department visits and unplanned hospitalizations in the treatment period for head and neck cancer patients treated with curative intent: A population-based analysis.
    Oral Oncol. 2018;83:107-114.
    PubMed     Abstract available


  538. WILKIE MD, Lau AS, Vlatkovic N, Jones TM, et al
    Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of TP53 mutation and therapeutic perspectives.
    Oral Oncol. 2018;83:1-10.
    PubMed     Abstract available


  539. GRONHOJ C, Jakobsen KK, Jensen DH, Rasmussen J, et al
    Pattern of and survival following loco-regional and distant recurrence in patients with HPV+ and HPV- oropharyngeal squamous cell carcinoma: A population-based study.
    Oral Oncol. 2018;83:127-133.
    PubMed     Abstract available


    July 2018
  540. DE BREE R, de Keizer B
    Is there a place for FDG-PET-CT in early oral cancer patients?
    Oral Oncol. 2018 Jul 31. pii: S1368-8375(18)30276.
    PubMed    


  541. FERRAROTTO R, William WN Jr, Tseng JE, Marur S, et al
    Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2018;82:83-90.
    PubMed     Abstract available


  542. RETTIG EM, Bishop JA, Agrawal N, Chung CH, et al
    HEY1 is expressed independent of NOTCH1 and is associated with poor prognosis in head and neck squamous cell carcinoma.
    Oral Oncol. 2018;82:168-175.
    PubMed     Abstract available


  543. HOROWITZ G, Hosni A, Yu E, Xu W, et al
    Prevalence, prognosis, and treatment implications of retropharyngeal nodes in unknown primary head and neck carcinoma.
    Oral Oncol. 2018;82:162-167.
    PubMed     Abstract available


  544. SIANO M, Espeli V, Mach N, Bossi P, et al
    Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial.
    Oral Oncol. 2018;82:144-151.
    PubMed     Abstract available


  545. MASSA ST, Rohde RL, Mckinstry C, Gresham M, et al
    An assessment of patient burdens from head and neck cancer survivorship care.
    Oral Oncol. 2018;82:115-121.
    PubMed     Abstract available


  546. PENG YL, Chen L, Shen GZ, Li YN, et al
    Interobserver variations in the delineation of target volumes and organs at risk and their impact on dose distribution in intensity-modulated radiation therapy for nasopharyngeal carcinoma.
    Oral Oncol. 2018;82:1-7.
    PubMed     Abstract available


    June 2018
  547. MAIR MD, Shetty R, Nair D, Mathur Y, et al
    Depth of invasion, size and number of metastatic nodes predicts extracapsular spread in early oral cancers with occult metastases.
    Oral Oncol. 2018;81:95-99.
    PubMed     Abstract available


  548. YUE Q, Zhang M, Chen Y, Zheng D, et al
    Establishment of prognostic factors in recurrent nasopharyngeal carcinoma patients who received salvage intensity-modulated radiotherapy: A meta-analysis.
    Oral Oncol. 2018;81:81-88.
    PubMed     Abstract available


  549. MOTT FE, Ferrarotto R, Nguyen T, Phan J, et al
    Nasopharyngeal carcinoma outcome with induction chemotherapy followed by concurrent chemoradiotherapy.
    Oral Oncol. 2018;81:75-80.
    PubMed     Abstract available


  550. RASMUSSEN JH, Hakansson K, Rasmussen GB, Vogelius IR, et al
    A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients.
    Oral Oncol. 2018;81:52-60.
    PubMed     Abstract available


  551. FERRIS RL, Blumenschein G Jr, Fayette J, Guigay J, et al
    Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Oral Oncol. 2018;81:45-51.
    PubMed     Abstract available


  552. OSAZUWA-PETERS N, Arnold LD, Loux TM, Varvares MA, et al
    Factors associated with increased risk of suicide among survivors of head and neck cancer: A population-based analysis.
    Oral Oncol. 2018;81:29-34.
    PubMed     Abstract available


  553. KRAEIMA J, Dorgelo B, Gulbitti HA, Steenbakkers RJHM, et al
    Multi-modality 3D mandibular resection planning in head and neck cancer using CT and MRI data fusion: A clinical series.
    Oral Oncol. 2018;81:22-28.
    PubMed     Abstract available


  554. LIN MC, Shueng PW, Chang WK, Mu-Hsin Chang P, et al
    Consensus and clinical recommendations for nutritional intervention for head and neck cancer patients undergoing chemoradiotherapy in Taiwan.
    Oral Oncol. 2018;81:16-21.
    PubMed     Abstract available


  555. SALOURA V, Vougiouklakis T, Sievers C, Burkitt K, et al
    The role of protein methyltransferases as potential novel therapeutic targets in squamous cell carcinoma of the head and neck.
    Oral Oncol. 2018;81:100-108.
    PubMed     Abstract available


  556. HANNA GJ, Kofman ER, Shazib MA, Woo SB, et al
    Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors.
    Oral Oncol. 2018;81:1-9.
    PubMed     Abstract available


    May 2018
  557. CARPENTER DJ, Mowery YM, Broadwater G, Rodrigues A, et al
    The risk of carotid stenosis in head and neck cancer patients after radiation therapy.
    Oral Oncol. 2018;80:9-15.
    PubMed     Abstract available


  558. BASHEER HA, Pakanavicius E, Cooper PA, Shnyder SD, et al
    Hypoxia modulates CCR7 expression in head and neck cancers.
    Oral Oncol. 2018;80:64-73.
    PubMed     Abstract available


  559. NULTON TJ, Kim NK, DiNardo LJ, Morgan IM, et al
    Patients with integrated HPV16 in head and neck cancer show poor survival.
    Oral Oncol. 2018;80:52-55.
    PubMed     Abstract available


  560. IOCCA O, Farcomeni A, Di Rocco A, Di Maio P, et al
    Locally advanced squamous cell carcinoma of the head and neck: A systematic review and Bayesian network meta-analysis of the currently available treatment options.
    Oral Oncol. 2018;80:40-51.
    PubMed     Abstract available


  561. HANEMAAIJER SH, van Gijn SE, Oosting SF, Plaat BEC, et al
    Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.
    Oral Oncol. 2018;80:33-39.
    PubMed     Abstract available


  562. LIN M, You R, Liu YP, Zhang YN, et al
    Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
    Oral Oncol. 2018;80:1-8.
    PubMed     Abstract available


    April 2018
  563. TARDY MP, Di Mauro I, Ebran N, Refae S, et al
    Microsatellite instability associated with durable complete response to PD-L1 inhibitor in head and neck squamous cell carcinoma.
    Oral Oncol. 2018 Apr 6. pii: S1368-8375(18)30124.
    PubMed    


  564. GARCIA-ESCUDERO R, Segrelles C, Duenas M, Pombo M, et al
    Overexpression of PIK3CA in head and neck squamous cell carcinoma is associated with poor outcome and activation of the YAP pathway.
    Oral Oncol. 2018;79:55-63.
    PubMed     Abstract available


  565. PENG H, Tang LL, Chen BB, Chen L, et al
    Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis.
    Oral Oncol. 2018;79:40-46.
    PubMed     Abstract available


  566. CAO C, Jiang F, Jin Q, Jin T, et al
    Locoregional extension and patterns of failure for nasopharyngeal carcinoma with intracranial extension.
    Oral Oncol. 2018;79:27-32.
    PubMed     Abstract available


  567. VAISANEN JA, Alho OP, Koivunen PT, Laara E, et al
    Cause-specific mortality in patients with head and neck cancer: Long-term follow-up of a population-based cohort from 1986 to 2012 accounting for competing risks.
    Oral Oncol. 2018;79:20-26.
    PubMed     Abstract available


  568. KAMAL M, Ng SP, Eraj SA, Rock CD, et al
    Three-dimensional imaging assessment of anatomic invasion and volumetric considerations for chemo/radiotherapy-based laryngeal preservation in T3 larynx cancer.
    Oral Oncol. 2018;79:1-8.
    PubMed     Abstract available


    March 2018
  569. GUPTA AA, Pande N, Kheur S, Raj AT, et al
    Assessing the potential role of scaffold-mediated local chemotherapy in oral cancer.
    Oral Oncol. 2018 Mar 16. pii: S1368-8375(18)30111.
    PubMed    


  570. MIZRACHI A, Migliacci JC, Montero PH, McBride S, et al
    Neck recurrence in clinically node-negative oral cancer: 27-year experience at a single institution.
    Oral Oncol. 2018;78:94-101.
    PubMed     Abstract available


  571. HAN MW, Ryu IS, Lee JC, Kim SH, et al
    Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer.
    Oral Oncol. 2018;78:56-63.
    PubMed     Abstract available


  572. CHAN JYW, Wong STS, Wei WI
    Real time indocyanin green near infrared lymphangiography for the reduction of drainage volume after neck dissection.
    Oral Oncol. 2018;78:52-55.
    PubMed     Abstract available


  573. XU C, Sun R, Tang LL, Chen L, et al
    Role of sequential chemoradiotherapy in stage II and low-risk stage III-IV nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy: A propensity score-matched analysis.
    Oral Oncol. 2018;78:37-45.
    PubMed     Abstract available


  574. LU S, Concha-Benavente F, Shayan G, Srivastava RM, et al
    STING activation enhances cetuximab-mediated NK cell activation and DC maturation and correlates with HPV(+) status in head and neck cancer.
    Oral Oncol. 2018;78:186-193.
    PubMed     Abstract available


  575. PARK YP, Jin L, Bennett KB, Wang D, et al
    CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma.
    Oral Oncol. 2018;78:145-150.
    PubMed     Abstract available


  576. RETZBACH EP, Sheehan SA, Nevel EM, Batra A, et al
    Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target.
    Oral Oncol. 2018;78:126-136.
    PubMed     Abstract available


  577. BRANDAO NETO JS, Aires FT, Dedivitis RA, Matos LL, et al
    Comparison between magnetic resonance and computed tomography in detecting mandibular invasion in oral cancer: A systematic review and diagnostic meta-analysis: MRI x CT in mandibular invasion.
    Oral Oncol. 2018;78:114-118.
    PubMed     Abstract available


  578. SLOOTER MD, Handgraaf HJM, Boonstra MC, van der Velden LA, et al
    Detecting tumour-positive resection margins after oral cancer surgery by spraying a fluorescent tracer activated by gamma-glutamyltranspeptidase.
    Oral Oncol. 2018;78:1-7.
    PubMed     Abstract available


    February 2018
  579. MUMTAZ S, Parrish J, Singh M
    Oculosympathetic paresis after selective neck dissection: A 'distant' complication.
    Oral Oncol. 2018 Feb 16. pii: S1368-8375(18)30042.
    PubMed    


  580. GOPINATH D, Menon RK
    Comments on "Compositional and functional variations of oral microbiota associated with the mutational changes in oral cancer" by Yang et al.
    Oral Oncol. 2018 Feb 10. pii: S1368-8375(18)30052.
    PubMed    


  581. PAI SI, Jack Lee J, Carey TE, Westra WH, et al
    HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.
    Oral Oncol. 2018;77:92-97.
    PubMed     Abstract available


  582. GIPSON BJ, Robbins HA, Fakhry C, D'Souza G, et al
    Sensitivity and specificity of oral HPV detection for HPV-positive head and neck cancer.
    Oral Oncol. 2018;77:52-56.
    PubMed     Abstract available


  583. HUO M, Panizza B, Bernard A, Porceddu SV, et al
    Head and neck squamous cell carcinoma of unknown primary: Outcomes of a pre-defined institutional treatment policy in a region with a high prevalence of skin cancer.
    Oral Oncol. 2018;77:43-48.
    PubMed     Abstract available


  584. MAJERCAKOVA K, Valero C, Lopez M, Garcia J, et al
    Postoperative staging of the neck dissection using extracapsular spread and lymph node ratio as prognostic factors in HPV-negative head and neck squamous cell carcinoma patients.
    Oral Oncol. 2018;77:37-42.
    PubMed     Abstract available


  585. KLEIN NULENT TJW, Noorlag R, Van Cann EM, Pameijer FA, et al
    Intraoral ultrasonography to measure tumor thickness of oral cancer: A systematic review and meta-analysis.
    Oral Oncol. 2018;77:29-36.
    PubMed     Abstract available


  586. AU KH, Ngan RKC, Ng AWY, Poon DMC, et al
    Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study).
    Oral Oncol. 2018;77:16-21.
    PubMed     Abstract available


  587. VAN DEN BOVENKAMP K, Dorgelo B, Noordhuis MG, van der Laan BFAM, et al
    Viable tumor in salvage neck dissections in head and neck cancer: Relation with initial treatment, change of lymph node size and human papillomavirus.
    Oral Oncol. 2018;77:131-136.
    PubMed     Abstract available


  588. DE FELICE F, de Vincentiis M, Luzzi V, Magliulo G, et al
    Late radiation-associated dysphagia in head and neck cancer patients: evidence, research and management.
    Oral Oncol. 2018;77:125-130.
    PubMed     Abstract available


  589. YANG SF, Huang HD, Fan WL, Jong YJ, et al
    Compositional and functional variations of oral microbiota associated with the mutational changes in oral cancer.
    Oral Oncol. 2018;77:1-8.
    PubMed     Abstract available


    January 2018
  590. WANG Y, Qin X, Zhu X, Chen W, et al
    Corrigendum to "Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway" [Oral Oncol. 76 (2018) 34-41].
    Oral Oncol. 2018 Jan 25. pii: S1368-8375(18)30015.
    PubMed    


  591. XU T, Zhou X, Shen C, Hu C, et al
    Suggestions for surveillance and radiation strategy in nasopharyngeal carcinoma treated with IMRT: Based on hazard-rate and patterns of recurrence.
    Oral Oncol. 2018;76:61-67.
    PubMed     Abstract available


  592. SZTURZ P, Wouters K, Kiyota N, Tahara M, et al
    Altered fractionation radiotherapy combined with concurrent low-dose or high-dose cisplatin in head and neck cancer: A systematic review of literature and meta-analysis.
    Oral Oncol. 2018;76:52-60.
    PubMed     Abstract available


  593. KUFTA K, Forman M, Swisher-McClure S, Sollecito TP, et al
    Pre-Radiation dental considerations and management for head and neck cancer patients.
    Oral Oncol. 2018;76:42-51.
    PubMed     Abstract available


  594. WANG Y, Qin X, Zhu X, Chen W, et al
    Oral cancer-derived exosomal NAP1 enhances cytotoxicity of natural killer cells via the IRF-3 pathway.
    Oral Oncol. 2018;76:34-41.
    PubMed     Abstract available


  595. MARCAZZAN S, Varoni EM, Blanco E, Lodi G, et al
    Nanomedicine, an emerging therapeutic strategy for oral cancer therapy.
    Oral Oncol. 2018;76:1-7.
    PubMed     Abstract available


  596. JANSEN L, Buttmann-Schweiger N, Listl S, Ressing M, et al
    Differences in incidence and survival of oral cavity and pharyngeal cancers between Germany and the United States depend on the HPV-association of the cancer site.
    Oral Oncol. 2018;76:8-15.
    PubMed     Abstract available


    December 2017
  597. VARELA-CENTELLES P, Garcia-Martin JM, Seoane-Romero J
    On the studies of time periods in head and neck cancer diagnosis and treatment.
    Oral Oncol. 2017 Dec 27. pii: S1368-8375(17)30415.
    PubMed    


  598. PENG H, Chen BB, Chen L, Chen YP, et al
    A network meta-analysis in comparing prophylactic treatments of radiotherapy-induced oral mucositis for patients with head and neck cancers receiving radiotherapy.
    Oral Oncol. 2017;75:89-94.
    PubMed     Abstract available


  599. VAN GINKEL JH, Slieker FJB, de Bree R, van Es RJJ, et al
    Cell-free nucleic acids in body fluids as biomarkers for the prediction and early detection of recurrent head and neck cancer: A systematic review of the literature.
    Oral Oncol. 2017;75:8-15.
    PubMed     Abstract available


  600. KULASINGHE A, Kenny L, Punyadeera C
    Circulating tumour cell PD-L1 test for head and neck cancers.
    Oral Oncol. 2017;75:6-7.
    PubMed     Abstract available


  601. JOSHI A, Patil V, Noronha V, Dhumal S, et al
    Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.
    Oral Oncol. 2017;75:54-60.
    PubMed     Abstract available


  602. CHENG SJ, Chang CF, Ko HH, Liu YC, et al
    Hypermethylated ZNF582 and PAX1 genes in oral scrapings collected from cancer-adjacent normal oral mucosal sites are associated with aggressive progression and poor prognosis of oral cancer.
    Oral Oncol. 2017;75:169-177.
    PubMed     Abstract available


  603. CHHABRIA KS, Carnaby GD
    Psychometric validation of the Center for Epidemiological Studies Depression Scale in Head and Neck Cancer patients.
    Oral Oncol. 2017;75:158-162.
    PubMed     Abstract available


  604. LI WF, Zhang Y, Liu X, Tang LL, et al
    Delayed clinical complete response to intensity-modulated radiotherapy in nasopharyngeal carcinoma.
    Oral Oncol. 2017;75:120-126.
    PubMed     Abstract available


  605. ASHIZAWA K, Yoshimura K, Johno H, Inoue T, et al
    Construction of mass spectra database and diagnosis algorithm for head and neck squamous cell carcinoma.
    Oral Oncol. 2017;75:111-119.
    PubMed     Abstract available


  606. KANG M, Zhou P, Liao X, Xu M, et al
    Prognostic value of masticatory muscle involvement in nasopharyngeal carcinoma patients treated with intensity-modulated radiation therapy.
    Oral Oncol. 2017;75:100-105.
    PubMed     Abstract available


  607. PARK YM, Lee DY, Oh KH, Cho JG, et al
    Clinical implications of pathologic factors after thyroid lobectomy in patients with papillary thyroid carcinoma.
    Oral Oncol. 2017;75:1-5.
    PubMed     Abstract available


    November 2017
  608. RAJ AT, Patil S, Sarode SC, Sarode GS, et al
    Evaluating the association between household air pollution and oral cancer.
    Oral Oncol. 2017 Nov 11. pii: S1368-8375(17)30363.
    PubMed    


  609. ECONOMOPOULOU P, Kotsantis I, Kyrodimos E, Lianidou ES, et al
    Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs).
    Oral Oncol. 2017;74:83-89.
    PubMed     Abstract available


  610. FADEN DL, Thomas S, Cantalupo PG, Agrawal N, et al
    Multi-modality analysis supports APOBEC as a major source of mutations in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;74:8-14.
    PubMed     Abstract available


  611. HAKANSSON K, Rasmussen JH, Rasmussen GB, Friborg J, et al
    A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments.
    Oral Oncol. 2017;74:77-82.
    PubMed     Abstract available


  612. SZTURZ P, Budikova M, Vermorken JB, Horova I, et al
    Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data.
    Oral Oncol. 2017;74:68-76.
    PubMed     Abstract available


  613. WARD MC, Shah C, Adelstein DJ, Geiger JL, et al
    Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer.
    Oral Oncol. 2017;74:49-55.
    PubMed     Abstract available


  614. MI JL, Zhang B, Pan YF, Su YX, et al
    Chemotherapy regimens containing taxanes or fluorouracil in nasopharyngeal carcinoma: Which better?
    Oral Oncol. 2017;74:34-39.
    PubMed     Abstract available


  615. DIRVEN R, Ebrahimi A, Moeckelmann N, Palme CE, et al
    Tumor thickness versus depth of invasion - Analysis of the 8th edition American Joint Committee on Cancer Staging for oral cancer.
    Oral Oncol. 2017;74:30-33.
    PubMed     Abstract available


  616. AJMANI GS, Nocon CC, Wang CH, Bhayani MK, et al
    Assessment of adjuvant therapy in resected head and neck cancer with high-risk features.
    Oral Oncol. 2017;74:15-20.
    PubMed     Abstract available


  617. TAO Y, Gross N, Liu Y, Zhang L, et al
    A high ratio of IL-12Rbeta2-positive tumor-infiltrating lymphocytes indicates favorable prognosis in laryngeal cancer.
    Oral Oncol. 2017;74:148-156.
    PubMed     Abstract available


  618. BONOMO P, Desideri I, Loi M, Lo Russo M, et al
    Elderly patients affected by head and neck squamous cell carcinoma unfit for standard curative treatment: Is de-intensified, hypofractionated radiotherapy a feasible strategy?
    Oral Oncol. 2017;74:142-147.
    PubMed     Abstract available


  619. PAPAKOSTAS P, Tsaousi G, Stavrou G, Rachovitsas D, et al
    Percutaneous endoscopic gastrostomy feeding of locally advanced oro-pharygo-laryngeal cancer patients: Blenderized or commercial food?
    Oral Oncol. 2017;74:135-141.
    PubMed     Abstract available


  620. SU TL, Chen AN, Leong CP, Huang YC, et al
    The effect of home-based program and outpatient physical therapy in patients with head and neck cancer: A randomized, controlled trial.
    Oral Oncol. 2017;74:130-134.
    PubMed     Abstract available


  621. PATINO MA, Ramirez RE, Perez CA, Feng L, et al
    The impact of intraoperative opioid use on survival after oral cancer surgery.
    Oral Oncol. 2017;74:1-7.
    PubMed     Abstract available


    October 2017
  622. WU M, Ou D, He X, Hu C, et al
    Corrigendum to "Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma" [Oral Oncol. 73 (2017) 118-123].
    Oral Oncol. 2017 Oct 11. pii: S1368-8375(17)30306.
    PubMed     Abstract available


  623. LI YC, Chen FP, Zhou GQ, Zhu JH, et al
    Incidence and dosimetric parameters for brainstem necrosis following intensity modulated radiation therapy in nasopharyngeal carcinoma.
    Oral Oncol. 2017;73:97-104.
    PubMed     Abstract available


  624. TSAI MS, Chen WC, Lai CH, Chen YY, et al
    Epigenetic therapy regulates the expression of ALDH1 and immunologic response: Relevance to the prognosis of oral cancer.
    Oral Oncol. 2017;73:88-96.
    PubMed     Abstract available


  625. WU SG, Liao XL, He ZY, Tang LY, et al
    Demographic and clinicopathological characteristics of nasopharyngeal carcinoma and survival outcomes according to age at diagnosis: A population-based analysis.
    Oral Oncol. 2017;73:83-87.
    PubMed     Abstract available


  626. HANNA GJ, Adkins DR, Zolkind P, Uppaluri R, et al
    Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2017;73:65-69.
    PubMed     Abstract available


  627. NAKANO K, Marshall S, Taira S, Sato Y, et al
    A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma.
    Oral Oncol. 2017;73:21-26.
    PubMed     Abstract available


  628. KIYOTA N, Hasegawa Y, Takahashi S, Yokota T, et al
    A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.
    Oral Oncol. 2017;73:138-146.
    PubMed     Abstract available


  629. WU M, Ou D, He X, Hu C, et al
    Long-term results of a phase II study of gemcitabine and cisplatin chemotherapy combined with intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2017;73:118-123.
    PubMed    


  630. FARQUHAR DR, Divaris K, Mazul AL, Weissler MC, et al
    Poor oral health affects survival in head and neck cancer.
    Oral Oncol. 2017;73:111-117.
    PubMed     Abstract available


  631. HUANG SF, Hsiao JH, Young CK, Chien HT, et al
    Familial aggregation of nasopharyngeal carcinoma in Taiwan.
    Oral Oncol. 2017;73:10-15.
    PubMed     Abstract available


  632. ZHAN KY, Eskander A, Kang SY, Old MO, et al
    Appraisal of the AJCC 8th edition pathologic staging modifications for HPV-positive oropharyngeal cancer, a study of the National Cancer Data Base.
    Oral Oncol. 2017;73:152-159.
    PubMed     Abstract available


    September 2017
  633. VEVE MP, Davis SL, Williams AM, McKinnon JE, et al
    Considerations for antibiotic prophylaxis in head and neck cancer surgery.
    Oral Oncol. 2017 Sep 21. pii: S1368-8375(17)30281.
    PubMed     Abstract available


  634. SAHOVALER A, Yeh D, Yoo J
    Primary facial reanimation in head and neck cancer.
    Oral Oncol. 2017 Sep 12. pii: S1368-8375(17)30246.
    PubMed     Abstract available


  635. DONA MG, Rollo F, Pichi B, Spriano G, et al
    Evaluation of the Xpert(R) HPV assay in the detection of Human Papillomavirus in formalin-fixed paraffin-embedded oropharyngeal carcinomas.
    Oral Oncol. 2017;72:117-122.
    PubMed     Abstract available


    July 2017
  636. BROGLIE MA, Jochum W, Michel A, Waterboer T, et al
    Evaluation of type-specific antibodies to high risk-human papillomavirus (HPV) proteins in patients with oropharyngeal cancer.
    Oral Oncol. 2017;70:43-50.
    PubMed     Abstract available


    June 2017
  637. DABAS S, Gupta K, Ranjan R, Sharma AK, et al
    Oncological outcome following de-intensification of treatment for stage I and II HPV negative oropharyngeal cancers with transoral robotic surgery (TORS): A prospective trial.
    Oral Oncol. 2017;69:80-83.
    PubMed     Abstract available


    May 2017
  638. DODD RH, Forster AS, Waller J, Marlow LAV, et al
    Discussing HPV with oropharyngeal cancer patients: A cross-sectional survey of attitudes in health professionals.
    Oral Oncol. 2017;68:67-73.
    PubMed     Abstract available


    April 2017
  639. LEVI S, Zini A, Fischman S, Czerninski R, et al
    Epidemiology of oral, salivary gland and pharyngeal cancer in children and adolescents between 1970 and 2011.
    Oral Oncol. 2017;67:89-94.
    PubMed     Abstract available


  640. ZHANG Y, Waterboer T, Haddad RI, Miles BA, et al
    Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment.
    Oral Oncol. 2017;67:77-82.
    PubMed     Abstract available


  641. CHAN OS, Kowanetz M, Ng WT, Koeppen H, et al
    Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer.
    Oral Oncol. 2017;67:52-60.
    PubMed     Abstract available


  642. LACAU ST GUILY J, Rousseau A, Baujat B, Perie S, et al
    Oropharyngeal cancer prognosis by tumour HPV status in France: The multicentric Papillophar study.
    Oral Oncol. 2017;67:29-36.
    PubMed     Abstract available


    March 2017
  643. PORCEDDU SV, Milne R, Brown E, Bernard A, et al
    Validation of the ICON-S staging for HPV-associated oropharyngeal carcinoma using a pre-defined treatment policy.
    Oral Oncol. 2017;66:81-86.
    PubMed     Abstract available


    February 2017
  644. GELTZEILER M, Clayburgh D, Gleysteen J, Gross ND, et al
    Predictors of extracapsular extension in HPV-associated oropharyngeal cancer treated surgically.
    Oral Oncol. 2017;65:89-93.
    PubMed     Abstract available


  645. GENTILE MS, Yip D, Liebsch NJ, Adams JA, et al
    Definitive proton beam therapy for adenoid cystic carcinoma of the nasopharynx involving the base of skull.
    Oral Oncol. 2017;65:38-44.
    PubMed     Abstract available


    January 2017
  646. O'HARE J, Maclean J, Szczesniak M, Gupta R, et al
    Laryngeal tumours and radiotherapy dose to the cricopharyngeus are predictive of death from aspiration pneumonia.
    Oral Oncol. 2017;64:9-14.
    PubMed     Abstract available


  647. OWOSHO AA, Tsai CJ, Lee RS, Freymiller H, et al
    The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): The Memorial Sloan Kettering Cancer Center experience.
    Oral Oncol. 2017;64:44-51.
    PubMed     Abstract available


  648. MARTEL M, Alemany L, Taberna M, Mena M, et al
    The role of HPV on the risk of second primary neoplasia in patients with oropharyngeal carcinoma.
    Oral Oncol. 2017;64:37-43.
    PubMed     Abstract available


    December 2016
  649. JEANNON JP, Tanaka A, Thavaraj S, Guerrero-Urbano T, et al
    ATR gene mutations in HPV negative oropharyngeal cancer.
    Oral Oncol. 2016 Dec 22. pii: S1368-8375(16)30244.
    PubMed    


  650. CHERA B, Wang K, Monroe A, Galloway T, et al
    Truth or myth: Definitive chemoradiotherapy doesn't work for HPV/p16 negative oropharyngeal squamous cell carcinoma?
    Oral Oncol. 2016 Dec 16. pii: S1368-8375(16)30234.
    PubMed    


    November 2016
  651. MIRGHANI H, Casiraghi O, Guerlain J, Amen F, et al
    Diagnosis of HPV driven oropharyngeal cancers: Comparing p16 based algorithms with the RNAscope HPV-test.
    Oral Oncol. 2016;62:101-108.
    PubMed     Abstract available


    September 2016
  652. D'SOUZA G, Zhang Y, Merritt S, Gold D, et al
    Patient experience and anxiety during and after treatment for an HPV-related oropharyngeal cancer.
    Oral Oncol. 2016;60:90-5.
    PubMed     Abstract available


  653. CHATURVEDI AK, D'Souza G, Gillison ML, Katki HA, et al
    Burden of HPV-positive oropharynx cancers among ever and never smokers in the U.S. population.
    Oral Oncol. 2016;60:61-7.
    PubMed     Abstract available


    July 2016
  654. SABER CN, Gronhoj Larsen C, Dalianis T, von Buchwald C, et al
    Immune cells and prognosis in HPV-associated oropharyngeal squamous cell carcinomas: Review of the literature.
    Oral Oncol. 2016;58:8-13.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Otorhinolaryngology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: